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Organometallic allylation for the formation of C-C bonds has been a widely 
developed area over the past several decades for the formation of homoallylic alcohols and 
amines. One such pathway, the eponymous Hosomi-Sakurai reaction involves the Lewis 
acid-catalyzed addition of an allylic silane to an acetal, carbonyl, or imine. This work 
demonstrates an example of a Hosomi-Sakurai reaction using 1,2-ditosyl diazetidine as a 
slow release formaldimine precursor with good yield and high selectivity. 
Another less classical field, C-H activation, has also been around for several 
decades, but has recently exploded in new innovations.  Through C-H activation chemists 
are able to bypass the need for functional groups that are substituted out, but instead utilizes 
the C-H bond as a synthon for further functionalization. This work will also demonstrate a 
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1.1 Novel formaldimine precursor for use in a Hosomi-Sakurai reaction for the 
formation of phenyl-substituted homoallylamines 
 
Allylation and aminomethylation are two very effective methods for C-C bond 
construction involving both a nucleophile and an electron deficient carbonyl or imine bond. 
Both of these types of reactions have been reviewed extensively with numerous examples 
containing good to excellent yields and high stereoselectivity.1-3 For most of these reactions 
the electron deficient carbonyl or imine needs to be activated by a Lewis acid, or 
alternatively the nucleophile can be activated by a Lewis base. These activating species 
can also significantly affect factors such as diastereoselectivity and regioselectivity. In 
addition to Lewis acid activation, the choice of imine substrate is also an immense factor 
governing reactivity and/or selectivity. A highly hindered substrate can strongly affect the 
approach of the nucleophile while a less hindered substrate may increase reactivity. As an 
extension of this, we report herein a method to utilize 1,2-ditosyl diazetidine, a four 
membered heterocycle that our group previously produced,4 to generate the electron 








Scheme 1.1 Formation of homoallylic alcohols via organometallic allylation7 
 
Organometallic allylations have had a long tradition in organic chemistry and 
typically involve a nucleophile consisting of an allylic olefin (1) attacking an electrophilic 
carbonyl (2) or imine substrate. While this topic has been widely studied and reviewed I 
will present the notable features related to the nucleophiles and substrates used herein. Very 
often these allylic nucleophiles contain an activating species in a terminal position (Sn, Si, 
B, etc.). The choice of end-group plays an immense factor in nucleophile activity, 
intermediate stability, and enantioselectivity and these attributes have been reviewed 
extensively.1,2 These reactions have been developed over the past century to demonstrate 
both effective yields and high enantioselectivity. End-group silanes increase the 
effectiveness of nucleophilic addition through the stabilizing β-silicon effect.8 
Additionally, stannic species, which have also been utilized very commonly, demonstrate 
a stabilization through both steric and electronic effects. The nucleophilic olefin attacks 
generating an acyclic synclinal transition state to minimize steric interactions while at the 
same time demonstrating a stabilizing interaction between the allylic HOMO and the 





strongly affected. Through the variation of the metal at the end of the allylic species 
scientists have demonstrated strongly syn enantioselectivity with Si, Sn, and B species, 
while Cr, Zn, and In show strong anti-selectivity. However, activating chiral Lewis acids 
and Lewis bases can override these preferences.10,11 Through organometallic allylation 
scientists have been able to form an array of homoallylic alcohols and amines. 
 
 
Scheme 1.2 Organometallic allylation with a closed transition state1 
 
One specific type of organometallic allylation that has been popular over the past 
few decades is the Hosomi-Sakurai reaction. Demonstrated initially by Hideki Sakurai6 in 
1976, this reaction uses an allylic silane (8) to react with a Lewis acid activated carbonyl 
(7), imine or acetal in a stepwise fashion. After the initial addition of the allylic nucleophile, 
the compound forms a cationic transition state, which is stabilized by a hyperconjugative 
beta-silicon effect.8 Next the silyl species is cleaved resulting in a homoallylic alcohol (9) 
or amine. The reaction pathway is able to proceed through either a closed or open transition 
state depending on which activating Lewis acid used. Observed stereoselectivity is 
significantly higher for reactions proceeding through the closed transition state due to the 






Scheme 1.3 Hosomi-Sakurai reaction6 
 
Though several examples of Hosomi-Sakurai reactions exist throughout literature, 
fewer have utilized a catalytic amount of Lewis acid with imines.5,13 Indeed there are 
several variations on the Hosomi-Sakurai reaction that involve various silanes, Lewis acids, 
and choices of substrate. While most Hosomi-Sakurai reactions involve the use of 
aldehydes as the substrate, there are numerous examples where both acetals and imines are 
used.6,14 These imine substrates react in a similar manner as aldehydes, however nitrogen 
can be a limiting factor in some cases as it often interferes with Lewis acid catalyzed 
pathways due to its basic nature.15 This obstacle in organometallic allylation, however, has 
been overcome and Lewis acid catalyzed Hosomi-Sakurai reactions with imine substrates 
remain a very viable route to homoallylamines. 
Another reaction pathway very similar to an imine Hosomi-Sakurai reaction is 
hydroaminomethylation. Hydroaminomethylation involves the addition of a hydrogen, 








Scheme 1.4 An example of hydroaminomethylation through a reductive pathway17 
 
hydroaminomethylation including reductive amination, allylation, and Mannich type 
reactions, to name a few.17,18 In effect a Hosomi-Sakurai reaction with an imine substrate 
is also an example of hydroaminoalkylation. To this end, the use of formaldimine as the 
substrate would invariably result in a hydroaminomethylation since formaldimine’s alkyl 
species contains only one carbon. Such a reaction is not without precedent. In the 1940s, 
initial work utilizing Fe(CO)5 as a catalyst for hydroaminomethylation was carried out.19 
Since then significantly more work has been accomplished and has been well 
reviewed.17,20,21 In a recent publication in 2016, Michael Krische published a ruthenium-
catalyzed addition of dienes to formaldimine.22 In this work Krische uses a novel triazine 
precursor (15) to generate formaldimine in situ (Scheme 1.5). This precursor, as it turns 
out, was very useful for carrying out hydroaminomethylation as it bypassed selectivity 
issues due to the high reactivity of formaldimine. Another example of the use of a 







Scheme 1.5 Use of 1,3,5-tris(aryl)-hexahydro-1,3,5-triazine for regiospecific 
hydroaminomethylation22 
 
Kotake used TsCH2NHTs to generate formaldimine through base cleavage and 
demonstrated its utility by aminomethylating several nucleophiles including pyrroldines, 
ester-stabilized carbanions, and sulfone carbanions showing moderate to good yields. This 
method was again used by Zhou et al. and Sikriwal et al.24, 25 in a [2+2+2] catalytic 
formation of hexahydropyrimidines and in a synthesis of three epimers of penmacric acid 
respectively (Schemes1.6 and 1.7).  
 
 







Scheme 1.7 Synthesis of penmacric acid epimer25 
 
 Formaldimine, however, does suffer from an inherent propensity for instability and 
decreased selectivity due to its unhindered structure and highly electrophilic center. In an 
effort to create a source of formaldimine with higher selectivity, our group developed a 
method to utilize 1,2-ditosyl diazetidine as a slow release formaldimine precursor with high 
selectivity and reactivity. 1,2-ditosyl diazetidine is a four membered heterocyclic ring 
containing two nitrogens and two carbons. This variation in chemical bonds (C-N, N-N, C-
C) also presents the possibility of additional reactivity. Indeed, nitrogenous heterocycles 
comprise the majority of pharmaceutical compounds,26 which gives rise to the possibility 
that 1,2-ditosyl diazetidine being either in its original form or as a derivation could also be 
synthetically useful in the development of new medicines. Similar structures include both 
β-lactams and diazetidinones, which also hold medicinal value where heterocyclic ring 
systems are found in biologically important agents including antiobiotics.27 
 Herein we demonstrate the utilization of 1,2-ditosyl diazetidine as a selective 






1.2 New modular approach for the synthesis of half-sandwich ruthenium 
complexes 
 
Throughout the past several decades the world of chemistry has exploded with new 
ideas as well as new challenges. In the late twentieth century a new approach to linking 
two molecules together, palladium cross coupling (Scheme 1.8), emerged as an innovative 
leap forward in technology that replaced several classical methods with a method that is 
more gentle, selective, and facile.28 Indeed, the 2010 Nobel prize in chemistry was awarded 
to Richard Heck, Ei-Ichi Negishi, and Akira Suzuki for their remarkable accomplishments 
in this area.29 
 
 
Scheme 1.8 An example Heck reaction for palladium cross coupling28 
 
 More recently a new area has been growing that promises to likewise replace 
several classical methods with improved pathways of reactivity. This area, termed C-H 
activation, involves the cleavage of a C-H bond followed by the highly selective, 
subsequent, substitution for a functional group at the same position (Scheme 1.9).30 This 
pathway utilizes high atom economy and high selectivity with catalytic amounts of a metal 





groups in organic substitutions, thereby opening up a very large scope of potential 
reactivities. This area, however, also encounters significant difficulties.31 The C-H bond is 
very nonpolar and also very thermodynamically stable. As a result, utilizing it as a synthon 
can be very challenging and often requires toxic metals and/or harsh conditions. On the 
other hand, however, C-H activation removes the usage of a functional group as a reaction 
partner and thereby removes biproducts which allows for the removal of other potential 
waste streams. 
C-H activation generally employs two types of reactivity: the functionalization of 
previously unfunctionalized molecules (Scheme 1.9) and the functionalization of a 
substrate employing some sort of directing group (Scheme 1.10).32 To accomplish these 
functionalizations several different transition metal species have been employed including 
Rh, Pd, Ni, Co, Ir, as well as Ru. In addition, several different directing groups been used 
with impressive selectivity and good yields.32,33,34 These directing groups most typically 
employ either a phosphorous, nitrogen, or a sulfur species due to the high σ-donation as 
well as the π-accepting ability. As a result of the directing influence, most of the 
substitutions occur at positions ortho to the directing group (Scheme 1.10),35 however some 
cases have been shown that demonstrate meta substitution.36 In metal catalyzed C-H 







Scheme 1.9 C-H activation on an unfunctionalized benzene32 
 
 
Scheme 1.10 C-H activation to install vinyl groups ortho to an amide directing group on 
a phenyl ring36 
 
coordination to the directing group the metal forms the most stable metallocycle possible, 
which typically consists of a five or six membered ring and typically results in ortho 
substitution as a result of the metallocycle (Schemes 1.10 & 1.11).36 
 
 






 Several different transition metals have been used with varying results. Huw Davies 
has made a very effective use of rhodium carbenes in several syntheses, including one 
example substituting various groups onto unactivated alkanes.37 Additionally, Jin-Quan Yu 
has made a very effective use of palladium catalyzed C-H activation in functionalizing 
amido cyclopropanes using amino acid ligands to enhance stereoselectivity.38 Palladium 
has also been widely and effectively used in the area of C-H activation due to its weak 
coordinative properties and is one of the most common metals used in this area of 
chemistry.32,34 Ruthenium’s use as a catalyst in C-H activation has been growing as of late. 
In 1986 Larry Lewis demonstrated a very early example of ruthenium dependent C-H 
activation by arylating ethylene and propylene species with varying regioselectivities 
(Scheme 1.12).39 Later, a very significant work by Shinji Murai detailed the coupling of 
several different olefins with various aryl ketones (Scheme 1.13)40 demonstrating the very 
significant potential for this pathway to catalyze a very large range of reactions. Indeed, 
several additions to ruthenium catalyzed C-H activation have been forthcoming over the 








Scheme 1.12 Ruthenium catalyzed ortho directed C-H activation arylation of ethylene39 
 
 
Scheme 1.13 Highly regioselective ortho coupling of olefins and aryl ketone species42 
 
Herein we demonstrate a new modular approach to the construction of a series of 
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RESULTS & DISCUSSION FOR:  
NOVEL FORMALDIMINE PRECURSOR FOR USE IN A HOSOMI-SAKURAI 
REACTION FOR THE FORMATION OF PHENYL-SUBSTITUTED 
HOMOALLYLAMINES 
2.1 Results & discussion 
Our project began by first determining a metal catalyzed method for the opening of 
the ditosyl diazetidine ring 1 that our lab had previously developed.1 To accomplish this, 
we set up a series of reactions containing only ditosyl diazetidine, solvent, and a metal 
lewis acid (Scheme 2.1). After several hours at 100°C the reaction mixture was first tested 
by thin layer chromatography (TLC) to indicate whether ditosyl diazetidine was consumed 
and whether or not a new compound appeared, which would indicate ring opening 
reactions. Secondly, the mixture was analyzed by 1HNMR spectroscopy to verify any 
preliminary observations as well as to determine what product could have been formed 
from the retro [2+2] addition reaction. From this information we were able to prove that 
FeBr2 was the only Lewis acid to open the ditosyl diazetidine ring forming a trimer 2. 
While the trimer was not a desirable end-product, it indicated that formaldimine was 






Scheme 2.1 Ring opening and subsequent trimerization 
 
Table 2.1 Metal catalysts for ditosyl diazetidine 1 ring opening to form a trimer 2 
Metal catalyst Yield of trimer 
CoCl2 No reaction 
CuBr2 No reaction 
InCl3 No reaction 
FeBr2 Fully converted 
Sc(OTf)3 No reaction 
RuCl3 No reaction 
AlCl3 No reaction 
MnCl2 No reaction 
 
 
Once we demonstrated a method for the ring opening of ditosyl diazetidine, we then 
demonstrated its utility in a Hosomi-Sakurai reaction using allyltrimethyl silane and 
formaldimine from the ditosyl diazetidine. Fortunately, we found that FeBr2 was able to 
double, not only as the Lewis acid for ring opening, but also as the Lewis acid for the 
activation of the formaldimine in the Hosomi-Sakurai reaction. Initial attempts at the 
 
20 
reaction proved effective, however 1HNMR still indicated the presence of a trimethyl silyl 
group around 0 ppm. In order to mediate this problem, we included tetrabutylammonium 
fluoride as a fluoride ion source to remove the trimethylsilyl group as well as acetic acid 
as a proton source for the amine. This solved the problem and resulted in moderate yields 
for both the simple allyltrimethylsilane and also a methyl-substituted allyltrimethylsilane 
(Schemes 2.2 and 2.3 respectively). 
 
 




Scheme 2.3 Hosomi-Sakurai reaction using methyl-substituted allyltrimethylsilane 5 
 
Following our success, we then tested several different phenyl-substituted 
substrates 7a-p demonstrating low to excellent yields (Scheme 2.4 and Table 2.2).  Phenyl-
substituted homoallylamines have thus far required either harsh conditions or a toxic metal 
catalyst for their synthesis.2,3,4 In this work we were able to demonstrate a range of phenyl-
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substituted homoallylamines that used low-toxicity FeBr2, while at the same time requiring 
only mild conditions. These phenyl substituents mostly demonstrated yields from 50-80 %. 
A few substrates demonstrated yields considerably outside this range, however. Of the two 
substrates with low yields one substrate 7l carried a trifluoromethyl group at the ortho 
position and the other 7m carried two methoxy groups at the meta positions on the phenyl 
ring with yields of 36 %. Initially we had anticipated that electron rich substrates would 
result in increased yield, however 7m proves otherwise.  It is also clear that it is not a matter 
of the substrate being electron poor either as 7l shows. When compared to Hammett 
parameters it becomes very clear that neither electron donating substrates (7b and 7e) nor 
electron withdrawing (7i, 7c, and 7l) substrates dominate. Additionally, from comparing 
unsubstituted (7a) to very substituted substrates (7l), a minor pattern emerges where the 
more substituted substrate suffered low yield. However, considering the gap in yield 
between 7a and some higher yield substrates (7d and 7n) it is also clear that ortho 
substitution, as would be expected, does not control the extent of the reaction. These results 
indicate that the substituent factors affecting yield are likely a combination of steric and 
electronic factors. The two substrates 7d and 7n that were converted with very high yields 
both carried a chlorine atom at the ortho position. Truly, it is very interesting that the 






























After completing our substrate scope, we then attempted our reaction at a higher 
scale (1/2 gram) with similar results for both the allyltrimethyl silane and the methyl-
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substituted allyltrimethylsilane. This shows that such a method would conceivably also be 
useful at a large scale for industrial usage.                                                                                               
 
 
Scheme 2.5 ½ gram scale Hosomi-Sakurai reaction using formaldimine precursor 1 
 
2.2 Conclusion and future Work 
In this work we have demonstrated the utility of 1,2-distosyl diazetidine as a 
formaldimine precursor through a Hosomi-Sakurai reaction. In this work formaldimine 
was generated in a slow-release manner that resulted in high selectivity and good yields for 
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RESULTS & DISCUSSION FOR: 
A NEW MODULAR APPROACH FOR THE SYNTHESIS OF HALF-SANDWICH 
RUTHENIUM COMPLEXES 
3.1 Synthesis of para-substituted complexes 
 
To begin the synthesis of the complex ligand backbone, the bromide of dimethyl 5-
bromoisophthalate was converted to a BPin functional group by a Suzuki cross coupling 
reaction with bis(pinacolato)diboron. The reaction yielde d 1 quantitatively and numerous 
examples of a similar nature are extant in literature.1,2,3 While initial attempts were carried 
out using only a simple silica gel pad to filter out inorganic media, replacing the need for 
an aqueous workup, it was later determined that a silica gel column was a superior approach 
as the residual BPinBr had a similar polarity to 3 and would elute into the product mixture 





Scheme 3.1 Synthesis of dimethyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) 
isophthalate (1) 
 
1, in turn, was then used in another Suzuki cross coupling reaction to add a second 
phenyl ring. For this reaction we found that the effect of the solvent was very important 
getting substantially lower yield in our initial attempt with toluene/methanol/water 1:1:0.1 
(26% yield). We later screened various conditions for similar reactions (Table 1) and 
settled on a dioxane/water mix for the meta-substituted ligand (Scheme 5.3 & Table 5.1), 
which we then also began using in the para-substituted ligand. When tested in this scheme 
we observed very good yield (>80%). Later we also investigated altering the base and 
catalyst trying CsF and Pd(Ph3)4 resulting in a very slight increase in yield. In addition, we 
found that shortening the time for the reaction to 3 hours also improved the yield 
presumably due to decreased product homo-coupling (2). 
 
 




For the synthesis of meta-substituted ligands this step was altered using 1,3-
bromoiodobenzene instead of 1,4-bromoiodobenzene. This then resulted in a different 
shape 5 that was intended to create a different cavity size for the Ru metal and other 
potential substituents. This different cavity size could potentially affect the selectivity of 
our complexes in whichever potential reactivity they are later employed. The remainder of 





Scheme 3.3 Synthesis of dimethyl 3'-bromo-[1,1'-biphenyl]-3,5-dicarboxylate 15 
 
Table 3.1 Screening conditions for Scheme 3.3 
Catalyst Base Solvent Yield 
Pd(OAc)2, DPPF CsF Dioxane/H2O 2:1 82% 
Pd(Ph3)4 CsF Dioxane/H2O 2:1 81% 
Pd(OAc)2, DPPF K2CO3 Dioxane/H2O 2:1 86% 
 
Following the addition of a second phenyl ring another bromide group was also 






Scheme 3.4 Synthesis of dimethyl 4'-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)-[1,1'-
biphenyl]-3,5-dicarboxylate (3) 
 
 We attempted to react 3 in another Suzuki cross coupling to extend the aryl chain 
and add a phosphine moiety that would act as an anchor for the ruthenium metal due to its 
strong σ-donating and π-accepting abilites.4 However, we found that the BPin group was 
not reactive enough. As a result of this decreased reactivity we then converted the BPin 
group into a boronic acid group using NH4OAc and NaIO4 before carrying out another 
Suzuki cross coupling to yield 4. Unfortunately, this step suffered from lowered yield as a 
result of side product formation. After reaction screening, we discovered that the reaction 
time was very important and at least 2.5 hours were needed, where longer time lengths 
resulting in no desired product remaining at the end of the reaction. In addition, we tested 






Scheme 3.5 Synthesis of (3',5'-bis(methoxycarbonyl)-[1,1'-biphenyl]-4-yl)boronic acid 
(5) 
 
Table 3.2 Screening conditions for step two of figure 3.5 
Catalyst Base Solvent Yield 
Pd(OAc)2, DPPF K2CO3 THF/H2O 4:1 38% 
Pd(OAc)2, DPPF K2CO3 Dioxane/H2O 4:1 39% 
Pd(OAc)2, DPPF K2CO3 Toluene/MeOH/H2O 1.0:0.8/0.2 No reaction 
 
Following this reaction, we converted the diester groups into amide functionalities 
through a two-step process to yield the final ligand (5-9). The purpose of the amide was to 
provide a directing group that can potentially interact with targeted substrates for increased 
selectivity in future reactions.5 The first step of this installation involved the hydrolysis of 
the diester into a dicarboxylic acid using high temperature and strongly basic conditions 
(20 equivalents NaOH). This step required a significant amount of solvent (240 mL/g 
diester) to achieve solubility of all species but otherwise ran smoothly. Toward the closure 
of this work, however, our group began encountering the oxidation of the phosphine after 
the hydrolysis. This was presumably due to the high temperatures and/or some minor 
unnoticed alteration in procedure. It was important to circumvent this problem, however, 
since the phosphine oxides were unable to bind to the ruthenium metal center. The oxidized 
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phosphines were again reduced using 32 eq. of SiCl3 in toluene at reflux for 6 hours for a 
quantitative yield.5 
 The next step involved the use of PyBOP and DIPEA for the conversion of the 
dicarboxylic acid intermediate into the final amide. This step was run effectively in DMF 
as is commonly described in literature, however, ethyl acetate also proved similarly useful 
for many amines and did not require the removal of DMF by several water washes. The 
only limitation to using ethyl acetate was solubility, where the solution would begin as 









Figure 3.1 Ligands 5-9 and 18-22 
 
Once the ligand was synthesized, we then used it to coordinate RuCl3 xH2O in 





coordinated arene in the absence of light, which added the Ru metal onto the phosphine 
but not onto the aryl ring. After separation of the intermediate from the rest of the reaction 
media by silica gel column chromatography, 650 lumin light from a desk lamp was shone 
onto the intermediate which caused the Ru metal to finally add to the aryl species as well. 
Successful metalation was evident through both 1HNMR, 13CNMR, and 31PNMR 
spectroscopy as the chemical shifts for the aryl hydrogens moved upfield with the 
additional electron density from the Ru metal. Conversely, the phosphorous chemical shift 
moved downfield to 50 ppm from -13 ppm indicating an electron withdrawing effect from 
the Ru metal. After metalation it was observed that after a variable amount of time the 
complexes tended to develop a problem with serious insolubility in most solvents. It seems 
likely that these complexes were dimerizing when this occurs. Interestingly though, these 
complexes were still able to catalyze preliminary screening reactions becoming 
homogenous over the course of the reaction. It was discovered that these complexes would 
dissolve in a CHCl3/MeOH mix. Whenever several (~5-6) drops of MeOH were added to 
the CHCl3 the complex would begin to dissolve. Once the complexes were redissolved we 
discovered that they would again become soluble in CHCl3 for a time (usually a matter of 
days or several hours). This finding seems to support the idea that the complexes dimerize 
and evinces that the MeOH is able to break up the dimers. This solvent system was also 











Figure 3.2 Metal complexes 10-14 and 23-24 
 
Following synthesis these complexes both 25 and 27 demonstrated diastereomers. 





chromatography, however, the diastereomers of 27 proved nearly identical on silaca gel. 
Unfortunately, as a result of the high difficulty of separation, 27 was not separated into its 
isomeric forms. However, it does demonstrate further evidence that chirality can be 
controlled in these metal complexes. 
Upon inspection of the complexes 10-14 and 23-27 one can observe several 
different functionalities which are intended to provide the potential for various reactivities. 
The amide groups on each complex are intended to interact via hydrogen bonding or by 
dipole-dipole interactions with functional groups on the potential substrate thus linking the 
two species for the formation of a metallocycle intermediate and subsequent C-H 
activation. For complexes 26 and 13 the nearby ester groups would increase the N-H acidity 
possibly rendering them to higher selectivity with hydrogen bond acceptors. The 
diastereotopic complexes of 25 also present the possibility of asymmetric reactivity in the 
future. One other factor that would affect potential C-H activation is the steric bulk and 
shape resulting from the amide group and the linear vs. curved shape of the aryl backbone. 
These steric factors could direct the approach and the coordination of the potential substrate 
species thus leading to various forms of selectivity (e.g. interact with one functional group 
over another, meta vs. ortho substitution, etc.). Indeed, while hopeful, these ideas are very 




3.2 Conclusion and future work 
 
           Our group has demonstrated the synthesis of a range of ruthenium complexes with 
the potential for C-H activation. Each complex required 6 with high yields in each step 
except for the 5th step. Future work will be carried out in the utilization of these complexes 
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EXPERIMENTAL PROCEDURES FOR HOSOMI-SAKURAI 
 
4.1 General considerations: 
4.1.1 General experimental methods:  
Unless otherwise noted, all solvents were dried with sodium benzophenone and 
distilled before use. All reactions were set up under argon atmosphere, utilizing glassware 
that was flame-dried and cooled under vacuum. All non-aqueous manipulations were using 
standard Schlenk techniques. Reactions were monitored using thin-layer chromatography 
(TLC) on Silica Gel plates. Visualization of the developed plates was performed under UV 
light (254 nm) or KMnO4 stain. Silica-gel flash column chromatography was performed 
on SiliCycle Inc. 40-63 μm silica gel. 
 
4.1.2 Materials:  
Unless otherwise indicated, starting catalysts and materials were obtained from 
Sigma Aldrich, Oakwood, Strem, or Acros Co. Ltd. Moreover, commercially available 




4.1.3 Instrumentation:  
All NMR spectra were run at 500 MHz (13CNMR) in CDCl3 solution. 1H NMR 
spectra were internally referenced to TMS. 13C NMR spectra were internally referenced to 
the residual solvent signal. Data for 1H NMR are reported as follows: chemical shift (δ 
ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m= multiplet, br = broad), 
coupling constants (J) were reported in Hz. High resolution mass spectra (HRMS) were 
recorded on Bruker MicrOTOF-QII mass instrument (ESI & EI). Gas Chromatograph Mass 
Spectrometry analysis were done on Shimdzu GCMS- QP2010 and ESI was the ionization 
method.  
 
4.2 General procedure for the preparation of 1,2-ditosyl-1,2-diazetidine 
 
Scheme 4.1 Formation of ditosylhydrazine 
 
Tosyl chloride (174 mmol) was added to tosylhydrdazine (139 mmol) in 
dichloromethane (242 mL) in an ice bath. Pyridine (14.1 mL) was added dropwise in a 
temperature range of 0-10 0C. TLC analysis was done to monitor the reaction. A mixture 
of water (250 mL) and hexane (250 mL) was added to the solution and stirred vigorously 
for 30 minutes. The solution was then suction filtered and washed with a 1:1 ratio of 
acetone and water (100 ml). The crystals were then added to acetone (320 mL) and boiled 
at 80 0C. Water (150 mL) was added while stirring, and the solution was placed in an ice 
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bath for an hour. The solution was then suction filtered and washed with a small amount 
of cold diethyl ether.  
 
Scheme 4.2 Ring formation of 1,2-ditosyl diazetidine 
 
Under nitrogen atmosphere, butyl lithium (2.5 M in hexanes, 11.2 mL, 28 mmol) 
solution was added drop wise to a solution of 1,2-ditosylhydrazine (12.9 mmol) in 
anhydrous dimethylformamide (50 mL) at -200C via gas tight syringe, and let it stir for 15 
minutes. 1,2-Dibromoethane (1.33 mL, 15 mmol) was then added dropwise to the solution 
at -20 0C over 10 minutes. The solution was then stirred overnight at -20 0C. This solution 
was then allowed to warm to room temperature. The reaction mixture was then added to a 
mixture of water (240 mL) and ammonium chloride (4.8g, ~90 mmol) in a beaker. The 
solution was then vacuum filtered and washed with water (3 x 50 mL), and then washed 
with ethanol (3 x 50 mL). Then the solid were washed with dichloromethane (50 mL) into 
a clean filter flask, and the filtrate was collected as a yellow liquid. 25 mL of the 
dichloromethane was then evaporated from the solution. Ethanol (60 mL) was then added 
to the solution and the dichloromethane was completely evaporated from the solution. The 
solution containing the solid was then suction filtered and washed with ethanol (2 x 30 mL) 
and then washed with hexane (20 mL). 1,2-Ditosyl-1,2-diazetidine was produced in 70 % 
yield. 1HNMR (500 MHz, CDCl3) δ 7.93 (d, J = 8.3 Hz), 7.44 (d, J = 8.1 Hz), 3.69 (s), 
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2.51 (s). 13CNMR (126 MHz, CDCl3) δ 145.70, 130.35, 129.76, 129.30, 47.81, 21.84. 
HRMS (ESI) [M+Na] Clacd for C16H18N2O4S2:389.0600, found 389.0600. 
4.3 Catalytic synthesis of homoallylic amines with 1,2-Ditosyl-1,2-diazetidine and 




An oven dried Schlenk tube was charged with catalyst FeBr2 (2.2 mg, 10 mol %) and 1,2-
ditosyl-1,2-diazetadine (36.6 mg, 0.1 mmol). The Schlenk tube was vacuumed to remove 
air and filled with nitrogen.  The Teflon screw cap was replaced with a rubber septum and 
allyl trimethylsilane (0.3 mmol) and 1 mL of chlorobenzene were added and the Schlenk 
tube was then purged with nitrogen for 1 minute and the rubber septum was replaced with 
a Teflon screw cap.  1.5 equivalence H2O, 1.5 equivalence of acetic acid and 1.5 
equivalence of tetrabutylammonium fluoride were added to the reacton mixture and stirred 
for 1 hour.  The reaction mixture was purified by flash chromatography with 5:1 hexane 
and ethyl acetate as mobile phase (14.5 mg, 64% yield).  1HNMR (500 MHz, CDCl3) δ 
7.75 (d, J = 8.3 Hz, 1H), 7.31 (d, J = 8.2 Hz, 1H), 5.63 (ddt, J = 17.1, 10.2, 6.9 Hz, 1H), 
5.28 – 4.88 (m, 1H), 4.59 (t, J = 5.6 Hz, 1H), 3.02 (q, J = 6.6 Hz, 1H), 2.44 (d, J = 7.6 Hz, 
2H), 2.20 (q, J = 6.7 Hz, 1H).13CNMR (125 MHz, CDCl3) δ 143.44, 136.96, 134.18, 










Compound was formed using the previous method (22.6 mg, 47% yield).1 1HNMR (500 
MHz, CDCl3) δ 7.75 (d, J = 8.2 Hz, 2 H), 7.31 (d, J = 8.0 Hz, 2H), 4.72 (d, J = 75.4 Hz, 
1H), 4.52 (t, J = 5.5 Hz, 1H), 3.05 (dd, J = 12.8, 6.6 Hz, 2H), 2.43 (s, 3H), 2.15 (t, J = 6.7 
Hz, 2H), 1.60 (s, 3H). 13CNMR (125 MHz, CDCl3) δ 143.43, 141.48, 136.87, 129.71, 
127.14, 113.21, 40.52, 37.18, 21.74, 21.53 
 




Scheme 4.3 Synthesis of aryl triflates 
 
Phenyl triflate and its derivatives (R = H 1a, t-Bu 1b, 3-CF3 1c, 2-Cl 1d, 2-Me 1e, 4-Ph 
1h, 2-Cl, 4-OMe 1i, 3-5-OMe 1j, 4-NO2 1k, 4-F 1l, 2,6-Cl 1m, 2-CF3 1n, 4-Cl 1o, 4-Br 
1p) were prepared according to the literature method for low to excellent yields.1 Naphthyl 
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Scheme 4.4 Synthesis of phenyl-substituted allylsilanes 
 
Various trimethyl(2-arylallyl)silane derivatives were synthesized by Heck reaction with 
aryl triflate 1a-e, (1.25 mmol), allyltrimethylsilane (6.1 mmol), TEA (2 eq.), Pd(OAc.) (3 





Compound 2a was prepared according to the general literature method. 1HNMR (300 
MHz, CDCl3) δ 7.38 – 7.32 (m, 2H), 7.29 – 7.16 (m, 3H), 5.08 (d, J = 1.6 Hz, 1H), 4.82 (s, 








Compound 2b was prepared from 1b (2.70 g, 9.57 mmol) and allyl trimethylsilane (7.42 
mL, 46.7 mmol) forming a yellow liquid (1.62 g, 69%). 1HNMR (300 MHz, CDCl3) δ 
7.36-7.35 (m, 4H), 5.17 (d, J = 1.74 Hz, 1H), 4.86 (d, J = 1.56 Hz, 1H), 2.04 (d, J = 0.90 
Hz, 2H), 1.35 (s, 9H), -0.05 (s, 9H). 13CNMR (126 MHz, CDCl3) δ 150.16, 146.23, 139.70, 
128.09, 126.35, 125.92, 125.20, 125.15, 109.33, 34.48, 31.38, 25.96, -1.33. HRMS (ESI): 





Compound 2c was prepared from 1c (368 mg, 1.25 mmol) and allyl trimethylsilane (870 
µL, 5.47 mmol) forming a yellow liquid (96.5 mg, 30% yield). 1HNMR (500 MHz, CDCl3) 
δ 7.66 (s, 1H), 7.61 (d, J = 7.79 Hz, 1H), 7.53 (d, J = 7.76 Hz, 1H), 7.44 (t, J = 7.76 Hz, 
1H), 5.21 (s, 1H), 4.98 (s, 1H), 2.06 (s, 2H), -0.07 (s, 9H) 13CNMR (126 MHz, CDCl3) δ 
145.38 , 143.51,  130.52 (q, J = 32.06 Hz), 129.55, 128.84, 128.59, 124.25 (q, J = 272.79 
Hz), 123.89 (q, J = 3.82 Hz), 123.05 (q, J = 3.80 Hz), 111.60, 26.07, -1.46. HRMS (ESI): 






Compound 2d was prepared from 1d (326 mg, 1.25 mmol) and allyl trimethylsilane (970 
µL, 6.1 mmol) forming a yellow liquid (176.5 mg, 63% yield). 1HNMR (500 MHz, CDCl3) 
δ 7.39-7.34 (m, 1H), 7.27-7.17 (m, 3H), 5.08 (s, 1H), 4.91 (s, 1H), 2.07 (s, 2H), -0.07 (s, 
9H). 13CNMR (126 MHz, CDCl3) δ 146.21, 143.17, 131.90, 130.34, 129.75, 128.10, 






Compound 2e was prepared from 1e (300 mg, 1.25 mmol) and allyl trimethylsilane (970 
µL, 6.1 mmol) forming a yellow liquid (120.1 mg, 47% yield). 1HNMR (500 MHz, CDCl3) 
δ 7.18-7.15 (m, 4H), 5.04 (s, 1H), 4.80 (s, 1H), 2.38 (s, 3H), 1.94 (s, 2H), -0.06 (s, 9H). 
13CNMR (126 MHz, CDCl3) δ 147.80, 144.39, 134.49, 130.21, 128.41, 126.68, 125.35, 








Compound 2f was prepared from 1f (345 mg, 1.25 mmol) and allyl trimethylsilane (970µL, 
6.1 mmol) forming a yellow liquid (257.8 mg, 86% yield). 1HNMR (500 MHz, CDCl3) δ 
8.20 (d, J = 7.8 Hz, 1H), 7.93 – 7.84 (m, 1H), 7.79 (d, J = 8.2 Hz, 1H), 7.59 – 7.48 (m, 
2H), 7.48 – 7.43 (m, 1H), 7.38 (d, J = 7.0 Hz, 1H), 5.27 (d, J = 1.0 Hz, 1H), 5.07 (d, J = 
1.1 Hz, 2H), 2.19, -0.06 (s, 9H). 13CNMR (126 MHz, CDCl3) δ 146.79, 142.95, 133.96, 




Compound 2g was prepared from 1g (345 mg, 1.25 mmol) and allyl trimethylsilane 
(970µL, 6.1 mmol) forming a yellow liquid (170.9 mg, 57% yield).3 1HNMR (300 MHz, 
CDCl3) δ 7.94 – 7.81 (m, 3H), 7.66 (d, J = 8.6 Hz, 1H), 7.57 – 7.44 (m, 3H), 5.36 (s, 1H), 
5.05 (s, 1H), 2.21 (s, 2H), -0.00 (s, 9H). 13CNMR (126 MHz, CDCl3) δ 146.36, 139.93, 









Compound 2h was prepared from 1h (378 mg, 1.25 mmol) and allyl trimethylsilane 
(970µL, 6.1 mmol) forming a yellow liquid (177.7 mg, 53% yield). 1HNMR (500 MHz, 
CDCl3) δ 7.65 (d, J = 7.3 Hz, 2H), 7.61 – 7.56 (m, 2H), 7.52 (d, J = 8.1 Hz, 2H), 7.50 – 
7.45 (m, 2H), 7.40 – 7.34 (m, 1H), 5.25 (d, J = 1.1 Hz, 1H), 4.94 (s, 1H), 2.09 (s, 2H), -
0.02 (s, 9H). 13CNMR (126 MHz, CDCl3) δ 146.08, 141.65, 140.79, 139.93, 128.80, 





Compound 2i was formed from 1i (363 mg, 1.25 mmol) and allyl trimethylsilane (970µL, 
6.1 mmol) forming a dark orange liquid (181mg, 57% yield).  1HNMR (500 MHz, CDCl3) 
δ 7.15 (d, J = 8.5 Hz, 1H), 6.92 (s, 1H), 6.77 (d, J = 8.5 Hz, 1H), 5.05 (s, 1H), 4.88 (s, 1H), 
3.82 (s, 3H), 2.05 (s, 2H), -0.07 (s, 9H). 13CNMR (126 MHz, CDCl3) δ 158.95, 145.74, 








Compound 2j was formed from 1j (358 mg, 1.25 mmol) and allyl trimethylsilane (970µL, 
6.1 mmol) forming a dark orange liquid (228.6 mg, 91% yield). H1NMR (500 MHz, 
CDCl3) δ 6.58 (s, 2H), 6.40 (s, 1H), 5.15 (s, 1H), 4.88 (s, 1H), 3.83 (s, 6H), 2.00 (s, 2H), -
0.05 (s, 9H). C13NMR (126 MHz, CDCl3) δ 160.42, 146.60, 145.10, 110.23, 104.82, 99.05, 
55.30, 31.58, 26.21, 22.65, 14.11, -1.41. HRMS (ESI): Found m/z 273.1281. Calcd. for 




Compound 2k was formed from 1k (1.25 mmol, 339 mg) and allyl trimethyl silane (970µL, 
6.1 mmol) forming a dark orange liquid (178.8 mg, 61% yield). 1HNMR (500 MHz, 
CDCl3) δ 8.19 (d, J = 8.8 Hz, 2H), 7.56 (d, J = 8.9 Hz, 2H), 5.28 (d, J = 1.0 Hz, 1H), 5.07 
(d, J = 1.0 Hz, 1H), 2.07 (d, J = 0.9 Hz, 2H), -0.07 (s, 9H). 13CNMR (126 MHz, CDCl3) δ 
149.45, 145.01, 134.59, 129.32, 127.03, 126.25, 123.54, 123.52, 113.64, 25.98, -1.43. 








Compound 2l was formed from 1l (1.25 mmol, 305 mg) and allyl trimethylsilane (970µL, 
6.1 mmol) forming a yellow liquid (165 mg, 54% yield). H1NMR (500 MHz, CDCl3) δ 
7.39 (dd, J = 8.7, 5.5 Hz, 2H), 7.01 (t, J = 8.7 Hz, 2H), 5.10 (s, 1H), 4.88 (s, 1H), 2.02 (s, 
2H), -0.07 (s, 9H). 13CNMR (126 MHz, CDCl3) δ 162.18 (d, J = 245.7 Hz), 145.64, (d, J 




Compound 2m was formed from 1m (1.25 mmol, 369 mg) and allyl trimethylsilane 
(970µL, 6.1 mmol) forming a yellow liquid (137.8 mg, 43% yield). 1HNMR (500 MHz, 
CDCl3) δ 7.32 (d, J = 8.0 Hz, 2H), 7.12 (t, J = 8.0 Hz, 1H), 5.29 (d, J = 1.2 Hz, 1H), 4.94 
(s, 1H), 1.98 (d, J = 0.6 Hz, 2H), 0.04, (s, 9H). 13CNMR (126 MHz, CDCl3) δ 142.34, 






Compound 2n was formed from 1n (1.25 mmol, 368 mg) and allyl trimethylsilane (970µL, 
6.1 mmol) forming a colorless liquid (44.2 mg, 14% yield). 1HNMR (500 MHz, CDCl3) δ 
7.65 (d, J = 7.9 Hz, 1H), 7.48 (t, J = 7.5 Hz, 1H), 7.37 (t, J = 7.6 Hz, 1H), 7.29 (d, J = 6.5 
Hz, 1H), 5.07 (s, 1H), 4.87 (s, 1H), 1.98 (s, 2H), -0.03 (s, 9H). 13CNMR (126 MHz, CDCl3) 
δ 146.11, 143.98 (q, J = 2.1 Hz), 143.97, 131.29, 130.56, 127.50 (q, J = 30.2 Hz), 126.92, 




Compound 2o was formed from 1o (1.25 mmol, 326 mg) and allyl trimethylsilane (970µL, 
6.1 mmol) forming a colorless liquid (157.4 mg, 56% yield). 1HNMR (500 MHz, CDCl3) 
δ 7.36 (d, J = 8.7 Hz, 2H), 7.29 (d, J = 8.6 Hz, 2H), 5.14 (d, J = 1.4 Hz, 1H), 4.90 (d, J = 
1.1 Hz, 1H), 2.02 (d, J = 0.8 Hz, 2H), -0.07 (s, 9H). 13CNMR (126 MHz, CDCl3) δ 145.51, 




Compound 2p was formed from 1p (1.25 mmol, 337 mg) and allyl trimethylsilane (970µL, 
6.1 mmol) forming a yellow liquid (79.9 mg, 30% yield). 1HNMR (500 MHz, CDCl3) δ 
7.44 (d, J = 8.5 Hz, 2H), 7.29 (d, J = 8.0 Hz, 2H), 5.14 (d, J = 1.3 Hz, 1H), 4.90 (d, J = 1.0 
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Hz, 1H), 2.01 (s, 2H), -0.07 (s, 9H). 13CNMR (126 MHz, CDCl3) δ 145.56, 141.71, 131.19, 
127.98, 121.09, 110.69, 26.03, -1.39. 
 
General procedures for the synthesis of homoallylamines 
 
 
Scheme 4.5 Synthesis of substituted homoallylamines 
 
An oven dried Schlenk tube was charged with catalyst FeBr2 (10 mol %) and 1,2-ditosyl-
1,2-diazetadine(0.05 mmol). The Schlenk tube was then vacuumed to remove air followed 
by refilling with nitrogen.  The Teflon screw cap was replaced with a rubber septum and 
chlorobenzene (1mL) and silane (0.15 mmol) were added to the Schlenk tube. The Schlenk 
tube was then purged with nitrogen for 1 minute and the rubber septum was replaced with 
a Teflon screw cap.  The reaction mixture was then stirred at 90 oC for 12 h.  After the 12 
hours H2O (1.5 eq.), acetic acid (1.5 eq.), and tetrabutylammonium fluoride (1.5 eq) were 
added and the mixture was allowed to stir at room temperature for 1 hour. This was then 








Compound 3a was prepared from diazetidine (18.3 mg, 0.05 mmol) and 2a (28.6 mg, 0.15 
mmol) forming a yellow gel (23.6 mg, 78% yield). 1HNMR (500 MHz, CDCl3) δ 7.66 (d, 
J = 8.25 Hz, 2H), 7.31-7.23 (m, 7H), 5.34 (s, 1H), 5.03 (d, J = 1.05 Hz, 1H), 4.39 (br, 1H), 
3.05 (dt, J = 6.60 Hz, 2H), 2.66 (t, J = 6.76, 2H), 2.40 (s, 3H). 13CNMR (126 MHz, CDCl3) 
δ 144.41, 143.37, 139.52, 136.86, 129.68, 128.53, 127.87, 127.06, 126.03, 115.17, 41.30, 





Compound 3b was prepared from diazetidine (18.3 mg, 0.05 mmol) and 2b (37.0 mg, 0.15 
mmol) forming a yellow gel (19.2 mg, 54% yield). 1HNMR (500 MHz, CDCl3) δ 7.69-
7.66 (d, 2H), 7.32-7.29 (m, 1H), 7.27-7.23 (m, 3H), 7.23-7.19 (m, 1H), 5.33 (d, J = 0.99 
Hz, 1H), 4.98 (d, J = 1.05 Hz, 1H), 4.47 (t, J = 6.01 Hz, 1H), 3.06 (dt, J = 6.01 Hz, 2H), 
2.65 (t, J = 6.64 Hz, 2H), 2.40 (s, 3H), 1.31 (s, 9H). 13CNMR (126 MHz, CDCl3) δ 151.01, 
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144.05, 143.32, 136.97, 136.46, 129.66, 127.09, 125.67, 125.43, 114.45, 41.34, 35.21, 





Compound 3c was prepared from diazetidine (18.3 mg, 0.05 mmol) and 2c (38.8 mg, 0.15 
mmol) forming a yellow gel (24.3 mg, 66 % yield). 1HNMR (500 MHz, CDCl3) δ 7.68 (d, 
J = 8.16 Hz, 2H), 7.51 (d, J = 8.90 Hz, 2H), 7.45 (d, J = 7.81 Hz, 1H), 7.41 (t, J = 7.61 
Hz, 1H), 7.27-7.23 (m, 2H), 5.40 (s, 1H), 5.14 (s, 1H), 4.57 (t, J = 5.91 Hz, 1H), 3.05 (dt, 
J = 6.63 Hz, 5.91 Hz, 2H), 2.69 (t, J = 6.84 Hz, 2H), 2.40 (s, 3H). 13C NMR (126 MHz, 
CDCl3) ppm 13CNMR (126 MHz, CDCl3) δ 143.54, 143.23, 140.50, 136.72, 130.90 (q, J 
= 31.94 Hz), 129.71, 129.34, 129.05, 127.04, 124.52 (q, J = 3.65 Hz), 124.02 (q, J = 
273.42 Hz), 122.73 (q, J = 3.78 Hz), 116.634, 41.18, 35.12, 21.49. HRMS (ESI): Found: 










Compound 3d was prepared from diazetidine (18.3 mg, 0.05 mmol) and 2d (38.8 mg, 0.15 
mmol) forming a yellow gel (30.1 mg, 90% yield). 1HNMR (500 MHz, CDCl3) δ 7.70 (d, 
J = 8.15 Hz, 2H), 7.32 (d, J = 7.76 Hz, 1H), 7.30-7.25 (m, 2H), 7.21-7.13 (m, 2H), 7.02 
(dd, J = 7.38, 1.35 Hz, 1H), 5.22 (s, 1H), 5.08 (s, 1H), 4.49 (br, 1H), 2.97 (dt, J = 6.35, 
Hz, 2H), 2.59 (t, J = 6.50 Hz, 2H), 2.42 (s, 3H). 13CNMR (126 MHz, CDCl3) δ 144.07, 
143.42, 140.06, 136.89, 131.99, 130.15, 129.73, 129.71, 128.74, 127.12, 126.80, 118.79, 





Compound 3e was prepared from diazetidine (18.3 mg, 0.05 mmol) and 2e (30.7 mg, 0.15 
mmol) forming a yellow gel (23.6 mg, 75% yield). 1HNMR (500 MHz, CDCl3) δ 7.69 (d, 
J = 8.24 Hz, 2H), 7.28 (d, J = 8.02 Hz, 2H), 7.17-7.11 (m, 2H), 7.05 (dt, J = 6.99, 6.59, 
2.29 Hz, 1H), 6.84 (d, J = 7.50 Hz, 1H), 5.15 (d, J = 1.39 Hz, 1H), 4.95 (d, J = 1.37 Hz, 
1H), 4.44-4.35 (br, 1H), 2.98 (dt, J = 6.54, Hz, 2H), 2.48 (t, J = 6.59 Hz, 2H), 2.43 (s, 3H), 
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2.20 (s, 3H). 13CNMR (126 MHz, CDCl3) δ 146.12, 143.45, 141.10, 136.85, 134.75, 
130.36, 129.73, 128.21, 127.35, 127.11, 125.63, 116.88, 40.98, 37.30, 21.56, 19.76. 




Compound 3f was formed from diazetidine (18.3 mg, 0.05 mmol) and 2f (0.15 mmol, 50.5 
mg) forming a white solid (23.3 mg, 69% yield). 1HNMR (500 MHz, CDCl3) δ 7.86 (dd, 
J = 15.6, 8.0 Hz, 2H), 7.75 (d, J = 8.2 Hz, 1H), 7.62 (d, J = 8.1 Hz, 2H), 7.50 – 7.42 (m, 
2H), 7.35 – 7.30 (m, 1H), 7.21 (d, J = 8.0 Hz, 2H), 7.05 (d, J = 6.9 Hz, 1H), 5.39 (s, 1H), 
5.18 (s, 1H), 4.43 – 4.34 (br, 1H), 2.97 (dt, J = 6.4, 6.4 Hz, 2H), 2.66 (t, J = 6.6 Hz, 2H), 
2.40 (, 3H). 13CNMR (126 MHz, CDCl3) δ 144.93, 143.38, 139.20, 136.75, 133.74, 130.88, 
129.67, 128.50, 127.77, 127.04, 126.18, 125.89, 125.17, 118.49, 41.25, 38.04, 21.54. 












Compound 3g was formed from diazetidine (18.3 mg, 0.05 mmol) and 2g (0.15 mmol, 50.5 
mg) forming a white solid (24.1 mg, 71% yield). 1HNMR (500 MHz, CDCl3) δ 7.82 – 7.73 
(m, 3H), 7.67 (s, 1H), 7.60 (d, J = 8.2 Hz, 2H), 7.49 – 7.45 (m, 2H), 7.42 (dd, J = 8.6, 1.8 
Hz, 1H), 7.11 (d, J = 8.0 Hz, 2H), 5.50 (s, 1H), 5.15 (s, 1H), 4.44 (t, J = 5.8 Hz, (s, 1H), 
3.12 – 3.05 (m, 2H), 2.79 (t, J = 6.7 Hz, 2H), 2.29 (s, 3H). 13CNMR (126 MHz, CDCl3) δ 
144.15, 143.33, 136.57, 133.28, 132.95, 129.57, 128.17, 127.56, 126.99, 126.38, 126.19, 
124.87, 124.20, 115.86, 41.29, 35.20. HRMS (ESI): Found m/z 374.1184. Calcd. for 




Compound 3h was formed from diazetidine (18.3 mg, 0.05 mmol) and 2h (0.15 mmol, 
56.6 mg) forming a white solid (20.1 mg, 53% yield). 1HNMR (500 MHz, CDCl3) δ 7.67 
(d, J = 7.4 Hz, 2H), 7.58 (d, J = 7.7 Hz, 2H), 7.51 (d, J = 7.7 Hz, 2H), 7.47 – 7.42 (m, 2H), 
7.35 (t, J = 8.4 Hz, 3H), 7.27 – 7.20 (m, 2H), 5.41 (s, 1H), 5.06 (s, 1H), 4.52 (s, 1H), 3.08 
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(dt, J = 6.4, Hz, 2H), 2.70 (t, J = 6.7 Hz, 2H), 2.34 (s, 3H). 13CNMR (126 MHz, CDCl3) δ 
143.84, 143.40, 140.69, 140.46, 138.29, 136.82, 129.68, 128.87, 127.51, 127.17, 127.08, 
126.96, 126.44, 115.19, 41.34, 35.19, 21.50. HRMS (ESI): Found m/z 374.1184. Calcd. 




Compound 3i was formed from diazetidine (18.3 mg, 0.05 mmol) and 2i (0.15 mmol, 35.3 
mg) forming a yellow solid (23.2 mg, 70% yield). 1HNMR (500 MHz, CDCl3) δ 8.14 (d, 
J = 8.3 Hz, 2H), 7.67 (d, J = 8.1 Hz, 2H), 7.42 (d, J = 8.6 Hz, 2H), 7.26 (d, J = 4.8 Hz, 2H), 
5.49 (s, 1H), 5.25 (s, 1H), 4.45 (br, 1H), 3.06 (dt, J = 6.6, 6.6 Hz, 2H), 2.73 (t, J = 6.8 Hz, 
2H), 2.41 (s, 3H). 13CNMR (126 MHz, CDCl3) δ 147.28, 146.20, 143.69, 142.82, 136.71, 
129.74, 127.06, 126.86, 123.82, 118.51, 41.18, 35.17, 21.52. HRMS (ESI): Found m/z 






Compound 3j was formed from diazetidine (18.3 mg, 0.05 mmol) and 2j (0.15 mmol, 37.6 
mg) forming an orange gel (12.6 mg, 36% yield). 1HNMR (500 MHz, CDCl3) δ 7.67 (d, J 
= 8.1 Hz, 2H), 7.25 (d, J = 9.2 Hz, 4H), 6.42 – 6.36 (m, 3H), 5.34 (s, 1H), 5.02 (s, 1H), 
4.37 (s, 1H), 3.78, (s, 6H), 3.05 (dt, J = 6.5 Hz, 2H), 2.62 (t, J = 6.7 Hz, 2H), 2.41 (s, 3H). 
13CNMR (126 MHz, CDCl3) δ 160.82, 144.49, 143.39, 141.77, 136.86, 129.67, 127.04, 
115.49, 104.50, 99.63, 55.38, 41.34, 35.48, 21.53. HRMS (ESI): Found m/z 384.1237. 




Compound 3k was formed from diazetidine (18.3 mg, 0.05 mmol) and 2k (0.15 mmol, 
38.2 mg) forming a yellow gel (32.9 mg, 94% yield). 1HNMR (500 MHz, CDCl3) δ 7.70 
(d, J = 8.1 Hz, 2H), 7.28 (d, J = 8.1 Hz, 2H), 6.92 (d, J = 8.5 Hz, 1H), 6.86 (d, J = 2.3 Hz, 
1H), 6.69 (dd, J = 8.5, 2.4 Hz, 1H), 5.19 (s, 1H), 5.05 (s, 1H), 4.45 – 4.39 (m, 1H), 3.78 (s, 
3H), 2.95 (dt, J = 6.3 Hz, 2H), 2.56 (t, J = 6.4 Hz, 2H), 2.43 (s, 3H). 13CNMR (126 MHz, 
CDCl3) δ 159.40, 143.64, 143.39, 136.89, 132.56, 132.12, 130.66, 129.69, 127.12, 118.86, 
115.02, 112.85, 55.56, 40.87, 36.82, 21.55. HRMS (ESI): Found m/z 366.0925. Calcd. for 







Compound 3l was formed from diazetidine (18.3 mg, 0.05 mmol) and 2l (31.3 mg, 0.15 
mmol) forming a yellow gel (19.2 mg, 60% yield). H1NMR (500 MHz, CDCl3) δ 7.66 (d, 
J = 8.2 Hz, 2H), 7.29 – 7.20 (m, 4H), 6.96 (t, J = 8.7 Hz, 2H), 5.29(s, 1H), 5.02 (s, 1H), 
4.41 (d, J = 3.7 Hz, 1H), 3.08 – 2.99 (m, 2H), 2.64 (t, J = 6.7 Hz, 2H), 2.41 (s, 3H). C13NMR 
(126 MHz, CDCl3) δ 162.29 (d, J = 248.2 Hz), 161.30, 143.23 (d, J = 14.2 Hz), 136.54, 
135.32 (d, J = 3.3 Hz), 129.48, 127.52, 127.45, 126.86, 115.26, 115.09, 40.96, 35.15, 21.32. 




Compound 3m was formed from diazetidine (18.3 mg, 0.05 mmol) and 2m (38.9 mg, 0.15 
mmol) forming a yellow gel (23.8 mg, 64% yield). 1HNMR (500 MHz, CDCl3) δ 7.73 (d, 
J = 8.2 Hz, 2H), 7.32 – 7.25 (m, 4H), 7.16 – 7.11 (m, 1H), 5.36 (s, 1H), 5.08 (s, 1H), 4.68 
(t, J = 5.9 Hz, 1H), 3.07 (dt, J = 6.4, 5.9 Hz, 2H), 2.53 (t, J = 6.4 Hz, 2H), 2.43 (s, 3H). 
13CNMR (126 MHz, CDCl3) δ 143.43, 140.99, 139.01, 137.02, 133.98, 129.73, 128.97, 
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128.17, 127.13, 120.05, 40.82, 36.26, 21.56. HRMS (ESI): Found m/z 392.0245. Calcd. 




Compound 3n was formed from diazetidine (18.3 mg, 0.05 mmol) and 2n (38.8 mg, 0.15 
mmol) forming a yellow gel (18.1 mg, 49% yield). 1HNMR (500 MHz, CDCl3) δ 7.73 (d, 
J = 8.3 Hz, 2H), 7.62 (d, J = 7.8 Hz, 1H), 7.43 (t, J = 7.5 Hz, 1H), 7.37 (t, J = 7.6 Hz, 1H), 
7.30 (d, J = 8.0 Hz, 2H), 7.07 (d, J = 7.6 Hz, 1H), 5.18 (d, J = 0.8 Hz, 1H), 5.03 (s, 1H), 
4.48 (br, 1H), 3.09 – 3.02 (m, 2H), 2.52 (t, J = 6.7 Hz, 2H), 2.43 (s, 3H). 13CNMR (126 
MHz, CDCl3) δ 143.50 (q, J = 7.4 Hz), 140.75, 136.82, 131.51, 130.29, 129.76, 127.88 (q, 
J = 29.9 Hz), 127.44, 127.13, 126.34 (q, J = 5.3 Hz), 124.43 (q, J=274.7 Hz), 117.85, 
117.86, 40.69, 37.76, 21.55. HRMS (ESI): Found m/z 408.0640. Calcd. for 






Compound 3o was formed from diazetidine (18.3 mg, 0.05 mmol) and 2o (33.7 mg, 0.15 
mmol) forming a yellow gel (22.9 mg, 68% yield). 1HNMR (300 MHz, CDCl3) δ 7.65 (d, 
J = 7.9 Hz, 2H), 7.24 (d, J = 9.8 Hz, 4H), 7.18 (d, J = 8.4 Hz, 2H), 5.33 (s, 1H), 5.06 (s, 
1H), 4.48 – 4.39 (m, 1H), 3.02 (dt, J = 6.5, 6.5 Hz, 2H), 2.64 (t, J = 6.7 Hz, 2H), 2.42 (s, 
3H). 13CNMR (126 MHz, CDCl3) δ 143.52, 143.27, 137.88, 136.68, 133.73, 129.68, 
128.65, 127.34, 127.04, 115.73, 41.14, 35.14, 21.55. HRMS (ESI): Found m/z 374.0376. 





Compound 3p was formed from diazetidine (18.3 mg, 0.05 mmol) and 2p (0.15 mmol, 57 
mg) forming a yellow gel (27.1 mg, 71% yield). 1HNMR (500 MHz, CDCl3) δ 7.65 (d, J 
= 8.2 Hz, 2H), 7.39 (d, J = 8.5 Hz, 2H), 7.27 – 7.23 (m, 2H), 7.12 (d, J = 8.5 Hz, 2H), 5.34 
(s, 1H), 5.06 (s, 1H), 4.47 – 4.40 (m, 1H), 3.05 – 2.99 (m, 2H), 2.64 (t, J = 6.7 Hz, 2H), 
2.42 (s, 3H). 13CNMR (126 MHz, CDCl3) δ 143.53, 143.33, 138.36, 136.67, 131.61, 
129.69, 127.67, 127.04, 121.88, 115.81, 41.14, 35.09, 21.57. HRMS (ESI): Found m/z 
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EXPERIMENTAL PROCEDURES FOR RUTHENIUM COMPLEXES 
 
5.1 General considerations: 
5.1.1 General experimental methods:  
Unless otherwise noted, all solvents were dried with sodium benzophenone and 
distilled before use. All reactions were set up under argon atmosphere, utilizing glassware 
that was flame-dried and cooled under vacuum. All non-aqueous manipulations were using 
standard Schlenk techniques. Reactions were monitored using thin-layer chromatography 
(TLC) on Silica Gel plates. Visualization of the developed plates was performed under UV 
light (254 nm) or KMnO4 stain. Silica-gel flash column chromatography was performed 
on SiliCycle Inc. 40-63 μm silica gel. 
 
5.1.2 Materials:  
Unless otherwise indicated, starting catalysts and materials were obtained from 
Sigma Aldrich, Oakwood, Strem, or Acros Co. Ltd. Moreover, commercially available 




5.1.3 Instrumentation:  
All NMR spectra were run at 500 MHz or 300 MHz in CDCl3 solution. 1HNMR spectra 
were internally referenced to TMS. 13CNMR spectra were internally referenced to the 
residual solvent signal. Data for 1HNMR are reported as follows: chemical shift (δ ppm), 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m= multiplet, br = broad), 
coupling constants (J) were reported in Hz. High resolution mass spectra (HRMS) were 
recorded on Bruker MicrOTOF-QII mass instrument (ESI & EI). Gas Chromatograph Mass 
Spectrometry analysis were done on Shimdzu GCMS- QP2010 and ESI was the ionization 
method.  
 
5.2 Synthesis of para substituted complexes 
 
 
Scheme 5.1 Synthesis of dimethyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) 
isophthalate (1)1 
 
Solid starting materials, aryl bromide (5.46 g, 20 mmol), B2Pin2 (5.33 g, 21 mmol), 
DPPF (266.0 mg 0.48 mmol), palladium acetate (90.0 mg, 0.4 mmol), and potassium 
acetate (5.88 g, 60 mmol) were added to a schlenk tube followed by vacuum addition of 
nitrogen atmosphere. Liquid components, THF (40 mL) were then added through a septum 
and the reaction was stirred at 100°C overnight. The reaction was then diluted with hexane 
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and run through a silica pad (pure ethyl acetate) to remove inorganic materials. Next, the 
mixture was run through a silica gel column (5:1 hexane:ethyl acetate) to yield a white 
solid.  (6.2251 g, 97 % yield). 1HNMR (500 MHz, CDCl3) δ 8.77 (t, J = 1.8 Hz, 1H), 8.64 
(d, J = 1.7 Hz, 2H), 3.95 (s, 6H), 1.37 (s, 12H). 
 
 
Scheme 5.2 Synthesis of dimethyl 4'-bromo-[1,1'-biphenyl]-3,5-dicarboxylate (2) 
 
Solid starting materials, diester (1.0 g, 3.16 mmol), bromoiodobenzene (1.34 g, 
4.74 mmol), palladium acetate (14.2 mg, 0.06 mmol), DPPF (42.1 mg, 0.076 mmol), 
potassium carbonate (1.31 g, 9.99 mmol were added to a schlenk tube followed by vacuum 
addition of nitrogen atmosphere. Liquid components, dioxane (5 mL), H2O (2.5 mL) were 
then added through a septum and the reaction was stirred at 100oC for 3h. Dioxane was 
next evaporated out of the mixture and then the reaction was washed with water. The 
resulting aqueous phase was extracted with ethyl acetate (3x). The combined organic 
phases were then dried and evaporated and then separated using silica gel chromatography 
(hexane: ethyl acetate: DCM 8:1:1) to yield a solid product (829.3 mg, 75% yield). 
1HNMR (300 MHz, CDCl3) δ 8.67 (t, J = 1.4 Hz, 1H), 8.42 (d, J = 1.4 Hz, 2H), 7.62 (d, J 
= 8.5 Hz, 2H), 7.53 (d, J = 8.6 Hz, 2H), 3.98 (s, 6H). 13CNMR (126 MHz, CDCl3) δ 166.07, 
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140.73, 137.93, 132.19, 132.03, 131.34, 129.64, 128.75, 122.68, 52.53. HRMS (ESI): 
Found m/z 370.9889. Calcd. for C16H13BrO4Na: (M+Na) 370.9889 
 
 
Scheme 5.3 Synthesis of dimethyl 4'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
[1,1'-biphenyl]-3,5-dicarboxylate (3) 
 
Solid starting materials, diester (1.16 g, 3.32 mmol), B2Pin2 (917 mg, 3.49 mmol), 
palladium acetate (15.5 mg, 0.066 mmol), DPPF (45.8 mg, 0.080 mmol), potassium 
carbonate (1.012 g, 9.96 mmol) were added to a schlenk tube followed by vacuum addition 
of nitrogen atmosphere. Liquid components, THF (8 mL) were then added through a 
septum and the reaction was stirred at 100oC overnight. The inorganic media was next 
filtered out of the mixture by using a silica pad (ethyl acetate). The resultant solution was 
then evaporated and separated using silica gel chromatography (hexane: ethyl acetate 5:1) 
to yield a solid product (839.7 mg, 64 % yield). 1HNMR (300 MHz, CDCl3) δ 8.66, 8.48 
(d, J = 1.5 Hz), 7.92 (d, J = 8.1 Hz), 7.67 (d, J = 8.2 Hz), 3.98, 1.38. 13CNMR (126 MHz, 
CDCl3) δ 166.20, 141.72, 141.52, 135.48, 132.32, 131.19, 129.58, 126.41, 83.96, 83.49, 





Scheme 5.4 Synthesis of dimethyl 2''-(diphenylphosphaneyl)-[1,1':4',1''-terphenyl]-3,5-
dicarboxylate (4) 
 
Solid starting materials, boronic acid (314 mg,1.0 mmol), phosphine (376 mg,1.1 mmol), 
K2CO3 (420 mg, 3.0 mmol), palladium tetrakis triphenylphosphine (23 mg, 0.02 mmol) 
were added to a schlenk tube followed by vacuum addition of nitrogen atmosphere. Liquid 
components dioxane (4 mL) and water (1 mL) were then added through a septum and the 
reaction was stirred at 100oC for 30 min. The reaction was then washed with water. The 
resulting aqueous phase was then extracted three times with ethyl acetate. The combined 
organic layer was then dried and evaporated. Finally, the mixture was separated using silica 
gel chromatography to yield a solid product (199.0mg, 38% yield). 1HNMR (500 MHz, 
CDCl3) δ 8.65 (s, 1H), 8.48 (2H), 7.57 (d, J = 7.9 Hz, 2H), 7.43 (t, J = 7.4 Hz, 1H), 7.39 – 
7.36 (m, 8H), 7.32, 7.27 – 7.22 (m, 5H), 7.11 – 7.07 (m, 1H), 3.98 (s, 6H). 13CNMR (126 
MHz, CDCl3) δ 166.26, 147.48 (d, J=28.4 Hz), 141.78 (d=28.4 Hz), 141.57, 137.58 (d, 
J=19.9 Hz), 137.41, 135.89 (d, J= 14.3 Hz), 134.24, 133.92 (d, J=19.8 Hz), 132.21, 131.12, 
130.42 (d, J=4.0 Hz), 130.08 (d, 4.9 Hz), 129.28, 128.81, 128.56, 128.43 (d, J=6.8 Hz),  
127.61, 126.33, 52.45. 31PNMR (121 MHz, CDCl3) δ -13.45. HRMS (ESI): Found m/z 




Scheme 5.5 Synthesis of 2''-(diphenylphosphaneyl)-N3, N5-diphenyl-[1,1':4',1''-
terphenyl]-3,5-dicarboxamide (5) 
 
Solid starting materials, phosphine (50 mg, 0.1 mmol), PyBOP (124.9 mg, 0.24 mmol) 
were added to a schlenk tube followed by vacuum addition of nitrogen atmosphere. Liquid 
components, aniline (22 µL, 0.24 mmol), DIPEA (42 µL, 0.24 mmol), ethyl acetate (1 mL) 
were then added through a septum and the reaction was stirred at room temperature 
overnight. The reaction was then washed with aqueous ammonium chloride to quench the 
reaction and the aqueous phase was extracted with ethyl acetate (3x). The combined 
organic layer was then dried and evaporated. Finally, the mixture was separated using silica 
gel chromatography (6:1:1 hexane:ethyl acetate:DCM) to yield a solid product (46.6. mg, 
71 % yield). 1HNMR (500 MHz, CDCl3) δ 8.30 (s, 1H), 8.25 (s, 2H), 8.09 (s, 2H), 7.68 (d, 
J = 7.9 Hz, 3H), 7.57 (d, J = 7.5 Hz, 2H), 7.47 – 7.35 (m, 6H), 7.35 – 7.29 (m, 7H), 7.28 – 
7.22 (m, 7H), 7.19 (t, J = 7.4 Hz, 2H), 7.12 – 7.08 (m, 1H). 13CNMR (126 MHz, Acetone) 
δ 165.62, 148.61 (d, 28.9 Hz), 142.70 (d, 6.0 Hz), 141.93, 140.29, 139.09, 138.64 (d, 12.9),  
137.35, 137.32, 136.51 (d, J=15.4 Hz), 135.16, 134.50 (d, J=20.0 Hz), 131.39 (d, 4.1 Hz),  
131.08 (d, J=4.9 Hz), 129.99, 129.55, 129.49, 129.42 (d, J=4.5 Hz), 128.60, 127.24, 
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126.71, 124.75, 121.15, 121.09, 121.00. 31PNMR (202 MHz, Acetone) δ -14.02. HRMS 
(ESI): Found m/z 651.2190. Calcd. for C44H32N2O2P : (M-H) 651.2196 
 
 
Scheme 5.6 Synthesis of N3,N5-dibenzyl-2''-(diphenylphosphaneyl)-[1,1':4',1''-
terphenyl]-3,5-dicarboxamide (6) 
 
Solid starting materials, phosphine (50 mg, 0.1 mmol), PyBOP (124.9 mg, 0.24 mmol) 
were added to a schlenk tube followed by vacuum addition of nitrogen atmosphere. Liquid 
components, amine (26 µL, 0.24 mmol), DIPEA (42 µL, 0.24 mmol), ethyl acetate (1 mL) 
were then added through a septum and the reaction was stirred at room temperature 
overnight. The reaction was then washed with aqueous ammonium chloride to quench the 
reaction and the aqueous phase was extracted with ethyl acetate (3x). The combined 
organic layer was then dried and evaporated. Finally, the mixture was separated using silica 
gel chromatography (2:1 hexane:ethyl acetate) to yield a solid product (49.4 mg, 73 % 
yield). 1HNMR (500 MHz, CDCl3) δ 8.15 (d, J = 4.3 Hz, 2H), 7.48 (d, J = 6.8 Hz, 2H), 
7.44 – 7.37 (m, 2H), 7.36 – 7.18 (m, 24H), 7.13 – 7.06 (m, 1H), 6.87 – 6.77 (m, 2H), 4.60 
(s, 4H). 13CNMR (126 MHz, CDCl3) δ 166.54, 147.44 (d, J=28.6 Hz), 141.83, 141.71 (d, 
J=6.3 Hz), 138.13, 137.82, 137.43 (d, J=11.5 Hz), 135.80 (d, J=14.2 Hz), 135.13, 134.26, 
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133.85 (d, J=19.7 Hz), 131.65, 130.37 (d, J=3.9 Hz), 130.08 (d, J=5.0 Hz), 128.82, 128.73, 
128.70, 128.63, 128.54, 128.42 (d, J=6.8 Hz), 127.87, 127.60, 127.42, 126.33, 125.99, 




Scheme 5.7 Synthesis of 2''-(diphenylphosphaneyl)-N3,N5-bis(1-phenylethyl)-
[1,1':4',1''-terphenyl]-3,5-dicarboxamide (7) 
 
Solid starting materials, phosphine (100 mg, 0.2 mmol), PyBOP (250 mg, 0.48 mmol) were 
added to a schlenk tube followed by vacuum addition of nitrogen atmosphere. Liquid 
components, amine (60 µL, 0.48 mmol), DIPEA (90 µL, 0.48 mmol), dimethyl formamide 
(2 mL) were then added through a septum and the reaction was stirred at room temperature 
overnight. The reaction was then diluted with DCM (15 mL) washed with water (4 x 15 
mL). The organic layer was then dried and evaporated. Finally, the mixture was separated 
using silica gel chromatography (2:1 hexane:ethyl acetate) to yield a solid product (82mg, 
58 % yield). 1HNMR (500 MHz, CDCl3) δ 8.10 (s, 1H), 8.08 (s, 2H), 7.45 (d, J = 7.7 Hz, 
2H), 7.41 (s, 1H), 7.35 (d, J = 7.3 Hz, 5H), 7.30 (t, J = 6.8 Hz, 10H), 7.26 – 7.19 (m, 9H), 
7.10 – 7.06 (m, 1H), 6.72 (d, J = 7.6 Hz, 2H), 5.34 – 5.26 (m, 2H), 1.57 (d, J = 6.8 Hz, 
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6H). 13CNMR (126 MHz, CDCl3) δ 165.77, 147.47 (d, J=28.7 Hz), 142.87, 141.84, 141.71 
(d, J=6.2 Hz), 137.91, 137.45 (d, J=11.4 Hz), 135.75 (d, J=14.1 Hz), 135.32, 134.27, 133.86 
(d, J=19.8 Hz), 130.37 (d, J=3.8 Hz), 130.07 (d, J=4.9 Hz), 128.82, 128.73, 128.55, 128.42 
(d, J=6.8 Hz), 127.61, 127.49, 126.36, 126.31, 126.26, 123.92, 77.28, 77.03, 76.77, 49.57, 
21.70 31PNMR (202 MHz, CDCl3) δ -13.57. HRMS (ESI): Found m/z 708.2900. Calcd. 




Scheme 5.8 Synthesis of diethyl 2,2'-((2''-(diphenylphosphaneyl)-[1,1':4',1''-terphenyl]-
3,5-dicarbonyl)bis(azanediyl))diacetate (8) 
 
Solid starting materials, phosphine (200 mg, 0.4 mmol), PyBOP (500 mg, 0.96 mmol) 
and glycine ester (134.4 mg, 0.96 mmol) were added to a schlenk tube followed by 
vacuum addition of nitrogen atmosphere. Liquid components, DIPEA (180 µL, 0.96 
mmol), DMF (4 mL) were then added through a septum and the reaction was stirred at 
room temperature overnight. The reaction was then diluted with DCM (50 mL) washed 
with water (6 x 50 mL). The organic layer was then dried and evaporated. Finally, the 
mixture was separated using silica gel chromatography to yield a solid product (154.5 
mg, 57 % yield).1HNMR (500 MHz, CDCl3) δ 8.15 (s, 1H), 8.09 (d, J = 1.3 Hz, 2H), 
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7.45 – 7.39 (m, 3H), 7.37 – 7.32 (m, 2H), 7.32 – 7.27 (m, 6H), 7.25 – 7.20 (m, 6H), 7.09 
(dd, J = 7.3, 3.7 Hz, 1H), 4.29 – 4.21 (m, 8H), 1.31 (t, J = 7.1 Hz, 6H). 13CNMR (126 
MHz, CDCl3) δ 170.10, 166.98, 166.85, 147.56 (d, J=28.5 Hz), 141.60 (d, J=8.3 Hz), 
140.26, 137.86, 137.69, 137.48 (d, J=11.5 Hz), 135.83 (d, J=14.1 Hz), 134.56, 134.44, 
134.41, 134.24, 134.05, 133.87 (d, J=19.7 Hz), 133.38, 132.55, 132.02, 131.92, 131.69, 
131.62, 130.42, 130.34 (d, J=3.7 Hz), 130.11 (d, J=5.0 Hz), 129.03, 128.83 (d, J=9.1 Hz), 
128.54, 128.46, 128.41, 128.31, 127.55, 126.86, 126.77, 126.32, 125.95, 124.48, 124.14, 
77.28, 77.03, 76.77, 61.62, 61.60, 61.55, 61.53, 41.97, 29.70, 14.17. 31PNMR (202 MHz, 




Scheme 5.9 Synthesis of dimethyl 2,2'-((2''-(diphenylphosphaneyl)-[1,1':4',1''-
terphenyl]-3,5-dicarbonyl)bis(azanediyl))bis(3-methylbutanoate) (9) 
 
Solid starting materials, phosphine (58.3 mg, 0.12 mmol), PyBOP (143.5 mg, 0.29 mmol) 
and valine ester (46.7 mg, 0.29 mmol) were added to a schlenk tube followed by vacuum 
addition of nitrogen atmosphere. Liquid components, DIPEA (51.6 µL, 0.29 mmol), DMF 
(1 mL) were then added through a septum and the reaction was stirred at room temperature 
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overnight. The reaction was then diluted with DCM (15 mL) washed with water (6 x 15 
mL). The organic layer was then dried and evaporated. Finally, the mixture was separated 
using silica gel chromatography (2:1 hexane:ethyl acetate) to yield a solid product (21.1 
mg, 24 % yield). 1HNMR (500 MHz, CDCl3) δ 8.20 (s, 1H), 8.17 (s, 2H), 7.55 (d, J = 8.1 
Hz, 2H), 7.43 (t, J = 7.4 Hz, 1H), 7.39 – 7.36 (m, 1H), 7.36 – 7.28 (m, 9H), 7.28 – 7.22 (m, 
6H), 7.10 (dd, J = 7.5, 3.7 Hz, 1H), 6.75 (d, J = 8.6 Hz, 2H), 4.82 (dd, J = 8.6, 5.1 Hz, 2H), 
3.80 (s, 6H), 1.03 (dd, J = 9.9, 6.9 Hz, 12H). 13CNMR (126 MHz, CDCl3) δ 172.38, 166.40, 
147.45 (d, J=28.8 Hz), 142.19, 141.88 (d, J=6.1 Hz), 137.89, 137.42 (d, J=11.2), 135.90 
(d, J=14.1 Hz), 135.16, 134.22, 133.93 (d, J=19.8 Hz), 130.45 (d, J=3.9 Hz), 130.09 (d, 
J=4.9 Hz), 128.87, 128.81, 128.58, 128.44 (d, J=6.9 Hz), 127.63, 126.49, 124.21, 57.73, 
52.35, 31.66, 19.07, 18.11. 31PNMR (202 MHz, CDCl3) δ -13.49. HRMS (ESI): Found 
m/z727.2932. Calcd. for C44H44N2O6P : (M-H) 727.2932 
 
 
Scheme 5.10 Synthesis of aniline amide Ru complex (10)  
 
Phosphine ligand (38.5 mg, 0.059 mmol), Ru starting material (75.5 mg, 0.12 mmol), and 
CHCl3 (3 mL) were added to a small glass vial and stirred under dark conditions for 30 
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min. Following this, components were separated by silica gel chromatography (1:1 
CHCl3:EtOAc). The resulting red intermediate complex was then added to a small glass 
vial and stirred under a desk lamp (650 lumin) for 3h. This mixture was then separated by 
silica gel chromatography (1:1 CHCl3:EtOAc) to yield a yellow product (38.7 mg, 80 % 
yield). 1HNMR (300 MHz, CDCl3) δ 9.82 (s, 1H), 8.58 (s, 2H), 8.46 (s, 1H), 7.73 (d, J = 
7.4 Hz, 5H), 7.66 – 7.45 (m, 8H), 7.45 – 7.28 (m, 10H), 7.17 – 7.06 (m, 2H), 6.45 (d, J = 
5.7 Hz, 2H), 5.42 (d, J = 5.8 Hz, 2H). 13CNMR (126 MHz, CDCl3) δ 165.56, 144.41, 
144.02, 143.47 (d, 22.1 Hz), 138.36, 138.27, 136.67, 136.63, 135.63, 133.80 (d, J=9.9 Hz),  
133.18, 131.67, 131.11 (d, J=2.8 Hz), 130.32 (d, J=6.5 Hz), 130.15, 129.65, 129.25, 
128.99, 128.93, 128.31 (d, J=11.1 Hz), 127.54 (d, J=12.6 Hz), 127.34, 124.61, 120.84, 
120.74, 109.75, 104.60 (d, 15.4 Hz), 96.94, 80.66, 29.73. 31PNMR (202 MHz, CDCl3) δ 








Phosphine ligand (39 mg, 0.057 mmol), Ru starting material (73.8 mg, 0.11 mmol), and 
CHCl3 (3 mL) were added to a small glass vial and stirred under dark conditions for 30 
min. Following this, components were separated by silica gel chromatography (1:1 
CHCl3:EtOAc). The resulting red intermediate complex was then added to a small glass 
vial and stirred under a desk lamp (650 lumin) for 3h. This mixture was then separated by 
silica gel chromatography (1:1:0.05 CHCl3:EtOAc:MeOH) to yield a yellow product (15.8 
mg, 33 % yield). 1HNMR (500 MHz, CDCl3) δ 8.48 (d, J = 1.9 Hz, 2H), 8.32 (d, J = 1.7 
Hz, 1H), 7.73 (dd, J = 7.5, 2.5 Hz, 1H), 7.66 – 7.62 (m, 1H), 7.62 – 7.58 (m, 2H), 7.52 
(ddd, J = 11.5, 5.5, 3.6 Hz, 4H), 7.48 – 7.42 (m, 2H), 7.39 (dd, J = 10.4, 7.8 Hz, 8H), 7.35 
– 7.28 (m, 6H), 7.28 – 7.22 (m, 2H), 6.41 (d, J = 5.8 Hz, 2H), 5.43 (d, J = 5.7 Hz, 2H), 
4.62 (s, 4H). 13CNMR (126 MHz, CDCl3) δ 167.08, 144.49, 144.09, 143.59 (d, J=22.3 Hz), 
138.27, 135.93, 135.90, 135.51, 133.81 (d, J=9.9 Hz), 133.19, 131.67 (d, J=2.2 Hz), 131.10 
(d, J=2.9 Hz), 130.30 (d, J=6.8 Hz), 130.05, 129.81, 129.41, 128.61, 128.31 (d, J=11.0 Hz), 
127.83, 127.64, 127.54, 127.32, 126.95, 109.39 (d, J=3.4 Hz), 105.47 (d, J=15.1 Hz), 
96.64, 81.00, 44.18, 44.05, 29.75. 31PNMR (202 MHz, CDCl3) δ 53.76. HRMS (ESI): 







Scheme 5.12 Synthesis of phenylethylamide Ru complex (12)  
 
Phosphine ligand (50 mg, 0.070 mmol), Ru starting material (80.9 mg, 0.141 mmol), and 
CHCl3 (5 mL) were added to a small glass vial and stirred under dark conditions for 30 
min. Following this, components were separated by silica gel chromatography (1:1 
CHCl3:EtOAc). The resulting red intermediate complex was then added to a small glass 
vial and stirred under a desk lamp (650 lumin) overnight. This mixture was then 
separated by silica gel chromatography (1:1 CHCl3:EtOAc) to yield a yellow product 
(37.2 mg, 60 % yield). 1HNMR (500 MHz, CDCl3) δ 8.64 (s,2H), 8.25 (s, 1H), 7.71 
(1H), 7.69 – 7.51 (m, 8H), 7.51 – 7.35 (m, 10H), 7.35 – 7.18 (m, 9H), 7.05 (d, J = 7.5 Hz, 
2H), 6.37 (d, J = 5.8 Hz, 1H), 6.29 (d, J = 5.9 Hz, 1H), 5.37 (dd, J = 8.2, 6.1 Hz, 2H), 
5.32 – 5.21 (m, 2H), 1.58 (d, J = 6.9 Hz, 6H). 13CNMR (126 MHz, CDCl3) δ 165.34, 
144.70, 144.31, 143.59 (d, J=22.1 Hz), 143.20, 135.87, 135.65, 133.90, 133.84 (dd, 
J=9.8, 5.5 Hz), 133.78, 133.14, 131.51, 131.00 (d, J=2.8 Hz), 130.18, 130.08, 129.76, 
129.68, 129.36, 128.79, 128.65, 128.43-127.97 (m), 127.56, 127.46, 127.26, 126.30, 
126.14, 108.92 (d, J=3.1 Hz), 105.04 (d, J=14.1 Hz), 97.23, 96.53, 81.07 (d, J=14.0 Hz), 
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49.85, 22.22. 31PNMR (202 MHz, CDCl3) δ 53.91. HRMS (ESI): Found m/z 845.1637. 
Calcd. for C48H41Cl1N2O2PRu: (M-Cl) 845.1632 
 
 
Scheme 5.13 Synthesis of glycine Ru complex (13) 
 
Phosphine ligand (50 mg, 0.074 mmol), Ru starting material (95.7 mg, 0.15 mmol), and 
CHCl3 (5 mL) were added to a small glass vial and stirred under dark conditions for 30 
min. Following this, components were separated by silica gel chromatography (1:1 
CHCl3:EtOAc). The resulting red intermediate complex was then added to a small glass 
vial and stirred under a desk lamp (650 lumin) overnight. This mixture was then separated 
by silica gel chromatography (1:1 CHCl3:EtOAc) to yield a yellow product (22 mg, 35 % 
yield). 1HNMR (300 MHz, CDCl3) δ 8.53 (s, 2H), 8.33 (s, 1H), 7.73 (d, J = 5.0 Hz, 1H), 
7.69 – 7.48 (m, 9H), 7.48 – 7.31 (m, 6H), 6.46 (d, J = 5.2 Hz, 2H), 5.41 – 5.33 (m, 2H), 
4.19 (m, 8H), 1.30 – 1.20 (m, 6H) 13CNMR (126 MHz, CDCl3) δ 169.85, 169.83, 167.18, 
167.12, 144.49, 144.09, 143.63 (d, J=22.0 Hz), 135.57, 135.23 (d, J=3.8 Hz), 133.81 (d, 
J=9.8 Hz), 133.12, 131.61, 131.03 (d, J=2.9 Hz), 130.32, 130.22 (d, J=6.6 Hz), 129.86, 
129.46, 128.27 (d, J=10.9 Hz), 127.66, 127.56, 127.16, 109.29 (d, J=3.0 Hz), 105.24 (d, 
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J=15.1 Hz), 96.70 (d, J=2.6 Hz), 81.00, 61.42, 42.09, 41.98, 14.18. 31PNMR (202 MHz, 
CDCl3) δ 54.08. HRMS (ESI): Found m/z 809.1116. Calcd. for C40H37Cl1N2O6PRu: (M-
Cl) 809.1116  
 
Scheme 5.14 Synthesis of Valine Ru Complex (14) 
 
Phosphine ligand (10 mg, 0.014 mmol), Ru starting material (10 mg, 0.014 mmol), and 
CHCl3 (1 mL) were added to a small glass vial and stirred under dark conditions for 30 
min. Following this, components were separated by silica gel chromatography (2:1 
CHCl3:EtOAc). The resulting red intermediate complex was then added to a small glass 
vial and stirred under a desk lamp (650 lumin) overnight. This mixture was then separated 
by silica gel chromatography (1:1 CHCl3:EtOAc) to yield a yellow product (7.4 mg, 59 % 
yield). 1HNMR (500 MHz, CDCl3) δ 8.55 (s, 2H), 8.32 (s, 1H), 7.84 (d, J = 8.4 Hz, 1H), 
7.73 (d, J = 7.7 Hz, 1H), 7.64 (t, J = 7.0 Hz, 1H), 7.61 – 7.48 (m, 6H), 7.48 – 7.43 (m, 2H), 
7.43 – 7.36 (m, 3H), 6.47 – 6.41 (m, 2H), 5.40 (d, J = 5.8 Hz, 1H), 4.70 – 4.63 (m, 2H), 
3.77 (s, 6H), 1.04 (td, J = 6.9, 1.5 Hz, 12H). 13CNMR (126 MHz, CDCl3) δ 172.32, 167.16, 
144.59, 143.43, 135.59, 133.88, 133.82 (dd, J=9.6, 5.7 Hz), 133.81, 133.76, 133.22, 
131.58, 131.02 (d, J=4.6 Hz), 130.29, 128.31, 128.26 (dd, 11.2, 2.7 Hz), 128.22, 128.20, 
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127.49, 127.39, 126.84, 97.61, 96.75, 80.39, 58.66, 58.56, 52.19, 31.04, 19.20, 18.45. 
31PNMR (202 MHz, CDCl3) δ 53.33. HRMS (ESI): Found m/z 865.1744. Calcd. for 
C44H45ClN2O6PRu : (M-Cl) 865.1742 
5.3 Synthesis of meta-substituted complexes 
 
 
Scheme 5.15 Synthesis of dimethyl 3'-bromo-[1,1'-biphenyl]-3,5-dicarboxylate (15) 
 
Solid starting materials, diester (1.0 g, 3.16 mmol), 1,3-bromoiodobenzene (600 µL, 4.74 
mmol), palladium acetate (14.2 mg, 0.06 mmol), DPPF (42.1 mg, 0.076 mmol), potassium 
carbonate (1.34 g, 9.48 mmol were added to a schlenk tube followed by vacuum addition 
of nitrogen atmosphere. Liquid components, dioxane (5 mL), H2O (2.5 mL) were then 
added through a septum and the reaction was stirred at 100oC for 3h. Dioxane was next 
evaporated out of the mixture and then the reaction was washed with water. The resulting 
aqueous phase was extracted with ethyl acetate (3x). The combined organic phases were 
then dried and evaporated and then separated using silica gel chromatography (hexane: 
ethyl acetate: DCM 8:1:1) to yield a white solid product (941.6 mg, 85 % yield). 1HNMR 
(300 MHz, CDCl3) δ 8.68 (t, J = 1.5 Hz, 1H), 8.42 (d, J = 1.5 Hz, 2H), 7.80 (t, J = 1.7 Hz, 
1H), 7.62 – 7.52 (m, 2H), 7.36 (t, J = 7.9 Hz, 1H), 3.99 (s, 6H). 13CNMR (126 MHz, 
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CDCl3) δ 166.04, 141.12, 140.45, 132.23, 131.36, 131.22, 130.55, 130.24, 129.89, 125.84, 
123.17, 52.54. HRMS (ESI): Found m/z 349.0070. Calcd. for C16H14BrO4: (M+H) 
349.0070 
 
Scheme 5.16 Synthesis of dimethyl 3'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
[1,1'-biphenyl]-3,5-dicarboxylate (16) 
 
Solid starting materials, diester (1. 2 g, 3.44 mmol), B2Pin2 (917 mg, 3.61 mmol), 
palladium acetate (15.5 mg, 0.066 mmol), DPPF (45.8 mg, 0.080 mmol), potassium 
carbonate (1.012 g, 9.96 mmol) were added to a schlenk tube followed by vacuum addition 
of nitrogen atmosphere. Liquid components, THF (8 mL) were then added through a 
septum and the reaction was stirred at 100oC overnight. The inorganic media was next 
filtered out of the mixture by using a silica pad (ethyl acetate). The resultant solution was 
then evaporated and separated using silica gel chromatography (hexane: ethyl acetate 5:1) 
to yield a solid product (1.299 g, 95 % yield). 1HNMR (500 MHz, CDCl3) δ 8.65 (s, 1H), 
8.48 (s, 2H), 8.08 (s, 1H), 7.85 (d, J = 7.3 Hz, 1H), 7.74 (d, J = 7.7 Hz, 1H), 7.49 (t, J = 
7.5 Hz, 1H), 3.98 (s, 6H), 1.38 (s, 12H). 13CNMR (126 MHz, CDCl3) δ 166.30, 142.02, 
138.44, 134.64, 133.42, 132.45, 131.08, 130.06, 129.28, 128.42, 84.04, 52.44, 24.90. 




Scheme 5.17 Synthesis of dimethyl 2''-(diphenylphosphaneyl)-[1,1':3',1''-terphenyl]-3,5-
dicarboxylate (17) 
 
Solid starting materials, phosphine (376 mg, 110 mmol), boronic acid (314 mg, 1.0 mmol), 
potassium carbonate (420 mg, 3 mmol), palladium acetate (4.5 mg, 0.02 mmol), DPPF (13 
mg, 0.024 mmol) were added to a schlenk tube followed by vacuum addition of nitrogen 
atmosphere. Liquid components, THF (4 mL), H2O (1 mL) were then added through a 
septum and the reaction was stirred at 100oC for 2.5h. The reaction was then washed with 
water. The resulting aqueous phase was then extracted three times with ethyl acetate. The 
combined organic layer was then dried and evaporated. Finally, the mixture was separated 
using silica gel chromatography (10:1 hexane: ethyl acetate) to yield a solid product (170.8 
mg, 32 % yield). 1H NMR (500 MHz, CDCl3) δ 8.63 (d, J = 1.6 Hz, 1H), 8.30 (d, J = 1.6 
Hz, 2H), 7.56 (d, J = 7.8 Hz, 1H), 7.46 – 7.33 (m, 5H), 7.34 – 7.19 (m, 11H), 7.07 (dd, J = 
7.9, 3.8 Hz, 1H), 3.98 (d, J = 1.3 Hz, 6H). 13CNMR (126 MHz, CDCl3) δ 166.24, 147.35 
(d, J=27.1 Hz), 142.37 (d, J=5.7 Hz), 141.72, 138.24, 137.17 (d, J= 12.6 Hz), 134.05 (d, 
J=20.2 Hz), 133.80, 132.27, 131.01, 130.03 (d, J=4.1 Hz), 129.51 (d, J=4.0 Hz), 129.27, 
129.03, 128.80 (d, J=3.4 Hz), 128.71, 128.58, 128.41, 128.35, 128.27, 127.61, 125.84, 
52.41, 29.71. 31P NMR (121 MHz, CDCl3) δ -12.57. HRMS (ESI): Found m/z 529.1563. 




Scheme 5.18 Synthesis of 2''-(diphenylphosphaneyl)-N3,N5-diphenyl-[1,1':3',1''-
terphenyl]-3,5-dicarboxamide (18) 
 
Solid starting materials, phosphine (50 mg, 0.10 mmol), PyBOP (124.9 mg, 0.24 mmol) 
were added to a schlenk tube followed by vacuum addition of nitrogen atmosphere. Liquid 
components, amine (22 µL, 0.24 mmol), DIPEA (42 µL, 0.24 mmol), EtOAc (1 mL) were 
then added through a septum and the reaction was stirred at room temperature overnight. 
The reaction was then washed with water and extracted with ethyl acetate (3x). The 
combined organic layer was then dried and evaporated. Finally, the mixture was separated 
using silica gel chromatography (6:1:1 hexane: ethyl acetate:DCM) to yield a solid white 
product (43.9 mg, 67 % yield). 1HNMR (500 MHz, CDCl3) δ 8.19 (s, 2H), 8.16 (s, 1H), 
7.95 (s, 2H), 7.65 (d, J = 8.0 Hz, 4H), 7.50 (d, J = 7.6 Hz, 1H), 7.43 – 7.32 (m, 8H), 7.32 
– 7.13 (m, 14H), 7.06 (dd, J = 7.6, 3.8 Hz, 1H). 13CNMR (126 MHz, Acetone) δ 165.08, 
147.28 (d, J=27.9 Hz), 142.47 (d, J=5.9 Hz), 142.24, 137.92, 137.67, 137.24 (d, J=10.9 
Hz), 136.01, 135.89 (d, J=14.2 Hz), 133.89 (d, J=20.0 Hz), 130.07 (d, J=4.8 Hz), 129.65 
(d, J=3.3 Hz), 129.13, 128.86, 128.71, 128.68, 128.64, 128.61, 128.56, 128.42 (d, J=6.9 
Hz), 127.68, 125.86, 124.88, 123.99, 120.39. 31PNMR (202 MHz, Acetone) δ -13.34. 




Scheme 5.19 Synthesis of N3,N5-dibenzyl-2''-(diphenylphosphaneyl)-[1,1':3',1''-
terphenyl]-3,5-dicarboxamide (19) 
 
Solid starting materials, phosphine (50 mg, 0.10 mmol), PyBOP (124.9 mg, 0.24 mmol) 
were added to a schlenk tube followed by vacuum addition of nitrogen atmosphere. Liquid 
components, amine (26 µL, 0.24 mmol), DIPEA (42 µL, 0.24 mmol), EtOAc (1 mL) were 
then added through a septum and the reaction was stirred at room temperature overnight. 
The reaction was then washed with water and extracted with ethyl acetate (3x). The 
combined organic layer was then dried and evaporated. Finally, the mixture was separated 
using silica gel chromatography (2:1 hexane: ethyl acetate) to yield a solid white product 
(43.1 mg, 59 % yield). 1HNMR (500 MHz, CDCl3) δ 8.07 (s, 1H), 7.87 (s, 2H), 7.43 (d, J 
= 7.6 Hz, 1H), 7.32 (d, J = 7.5 Hz, 2H), 7.27 (d, J = 5.6 Hz, 12H), 7.23 – 7.17 (m, 6H), 
7.17 – 7.07 (m, 11 H), 6.98 (dd, J = 7.3, 3.4 Hz, 1H), 6.52 (t, J = 5.0 Hz, 2H), 4.56 (d, J = 
5.5 Hz, 4H). 13CNMR (126 MHz, CDCl3) δ 166.37, 147.30 (d, J=27.6 Hz), 142.33 (d, 
J=5.9 Hz), 142.13, 138.36, 137.80, 137.24 (d, J=11.4 Hz), 136.15, 136.03, 135.17, 134.71, 
133.99 (d, J=20.0 Hz), 133.86, 131.05, 130.02 (d, J=4.5 Hz), 129.51 (d, J=3.7 Hz), 128.83, 
128.76, 128.72, 128.63, 128.54, 128.39, 128.36 (d, J=7.0 Hz), 128.16, 128.00, 127.94, 
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127.75, 127.64, 127.40, 125.97, 124.12, 44.32. 31PNMR (202 MHz, CDCl3) δ -12.73. 
HRMS (ESI): Found m/z679.2499. Calcd. for C46H36N2O2P : (M-H) 679.2509. 
 
 
Scheme 5.20 Synthesis of 2''-(diphenylphosphaneyl)-N3,N5-bis(1-phenylethyl)-
[1,1':3',1''-terphenyl]-3,5-dicarboxamide (20) 
 
Solid starting materials, phosphine (50 mg, 0.10 mmol), PyBOP (124.9 mg, 0.24 mmol) 
were added to a schlenk tube followed by vacuum addition of nitrogen atmosphere. Liquid 
components, amine (30 µL, 0.24 mmol), DIPEA (42 µL, 0.24 mmol), EtOAc (1 mL) were 
then added through a septum and the reaction was stirred at room temperature overnight. 
The reaction was then washed with water and extracted with ethyl acetate (3x). The 
combined organic layer was then dried and evaporated. Finally, the mixture was separated 
using silica gel chromatography (2:1 hexane: ethyl acetate) to yield a solid product (42.1 
mg, 59 % yield) 1HNMR (300 MHz, CDCl3) δ 8.12 (s, 1H), 7.94 (s, 2H), 7.46 (d, J = 7.4 
Hz, 2H), 7.42 – 7.12 (m, 25H), 7.06 (dd, J = 7.2, 3.6 Hz, 1H), 6.60 (d, J = 7.6 Hz, 2H), 
5.41 – 5.24 (quint, 2.11), 1.58 (d, J = 6.8 Hz, 6H). 13CNMR (126 MHz, CDCl3) δ 165.67, 
147.23 (d, J=27.3 Hz), 142.84, 142.29 (d, J=5.9 Hz), 142.09, 138.49, 137.20, 137.13 (dd, 
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J=11.3 Hz), 137.06, 136.16 (d, J=14.7 Hz), 135.27, 134.05, 133.90, 133.86, 130.04 (d, 
J=4.6 Hz), 129.50 (d, J=3.8 Hz), 128.75, 128.57 (d, J=2.8 Hz), 128.39, 128.34, 128.30, 
127.61, 127.52, 126.27, 125.95, 124.01, 49.54, 21.69. 31PNMR (121 MHz, CDCl3) δ -
12.48. HRMS (ESI): Found m/z 707.2820. Calcd. for C48H40N2O2P : (M-H) 707.2822 
 
 
Scheme 5.21 Synthesis of diethyl 2,2'-((2''-(diphenylphosphaneyl)-[1,1':3',1''-terphenyl]-
3,5-dicarbonyl)bis(azanediyl))diacetate (21) 
 
Solid starting materials, phosphine (296.3 mg, 0.6 mmol), PyBOP (740.8 mg, 1.44 mmol) 
and glycine ester (200 mg, 1.44 mmol) were added to a schlenk tube followed by vacuum 
addition of nitrogen atmosphere. Liquid components, DIPEA (270µL, 1.44 mmol), DMF 
(6 mL) were then added through a septum and the reaction was stirred at room temperature 
overnight. The reaction was then diluted with DCM (50 mL) washed with water (6 x 50 
mL). The organic layer was then dried and evaporated. Finally, the mixture was separated 
using silica gel chromatography to yield a solid product (239.4 mg, 59 % yield). 1HNMR 
(500 MHz, CDCl3) δ 8.16 (s, 1H), 7.98 (s, 2H), 7.59 – 7.53 (m, 1H), 7.48 (d, J = 5.1 Hz, 
1H), 7.46 – 7.38 (m, 2H), 7.38 – 7.31 (m, 3H), 7.31 – 7.24 (m, 8H), 7.23 – 7.19 (m, 3H), 
7.06 (dd, J = 7.4, 3.6 Hz, 1H), 7.03 – 6.97 (m, 1H), 4.29 – 4.22 (m, 8H), 1.31 (t, J = 7.1 
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Hz, 6H). 13CNMR (126 MHz, CDCl3) δ 170.14, 170.03, 170.00, 166.67, 147.33 (d, J=27.6 
Hz), 142.34 (d, J=6.2 Hz), 142.03, 138.27, 137.24 (d, J=11.2 Hz), 136.15 (d, J=14.3 Hz), 
134.58, 134.56, 134.04 (d, J=20.0 Hz), 133.81, 130.09 (d, J=4.5 Hz), 129.55 (d, J=4.0 Hz), 
129.09, 128.97, 128.93, 128.74, 128.69, 128.56, 128.38 (d, J=6.9 Hz), 128.27, 128.21, 
127.59, 127.19, 125.91, 124.17, 124.01, 61.72, 41.99, 14.18. 31PNMR (202 MHz, CDCl3) 




Scheme 5.22 Synthesis of dimethyl 2,2'-((2''-(diphenylphosphaneyl)-[1,1':3',1''-
terphenyl]-3,5-dicarbonyl)bis(azanediyl))bis(3-methylbutanoate) (22) 
 
Solid starting materials, phosphine (385 mg, 0.82 mmol), PyBOP (1.02 g, 1.94 mmol) and 
valine ester (331.9 mg, 1.94 mmol) were added to a schlenk tube followed by vacuum 
addition of nitrogen atmosphere. Liquid components, DIPEA (270 µL, 1.44 mmol), DMF 
(6 mL) were then added through a septum and the reaction was stirred at room temperature 
overnight. The reaction was then diluted with DCM (50 mL) washed with water (6 x 50 
mL). The organic layer was then dried and evaporated. Finally, the mixture was separated 
using silica gel chromatography to yield a solid oxide intermediate (348.6 mg, 57 % yield) 
for the first step. Next the 100 mg of the intermediate was added into a Schlenk tube 
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followed by vacuum addition of nitrogen atmosphere. Liquid components, trichlorosilane 
(440 µL, 4.3 mmol), toluene (6 mL) were then added to through a septum and the reaction 
was stirred at reflux for 6h. The resulting mixture was then allowed to cool to room 
temperature. Next the mixture was neutralized by sodium bicarbonate (1 mL saturated 
aqueous solution) and stirred for 5min at room temperature before washing the mixture 
with water (15 mL) and extracting with ethyl acetate (3x15 mL). The combined organic 
phases were then dried and evaporated to yield a white solid (50.7 mg, 30% yield). 1HNMR 
(500 MHz, CDCl3) δ 8.20 (s, 1H), 8.03 (s, 2H), 7.52 (d, J = 7.7 Hz, 1H), 7.44 – 7.40 (m, 
2H), 7.39 – 7.33 (m, 2H), 7.31 – 7.19 (m, 14H), 7.06 (dd, J = 7.5, 3.8 Hz, 1H), 6.83 (d, J 
= 7.1 Hz, 2H), 4.81 (dd, J = 8.5, 5.2 Hz, 2H), 3.78 (s, 6H), 2.35 – 2.25 (m, 2H), 1.03 (dd, 
J = 10.7, 6.9 Hz, 12H). 13CNMR (126 MHz, CDCl3) δ 172.42, 166.51, 147.18 (d, J=26.9 
Hz), 142.39 (d, J=5.9 Hz), 138.49, 137.15, 137.09 (dd, J=11.3, 3.5 Hz), 137.03, 136.27 (d, 
J=14.6 Hz), 135.05, 134.05 (d, J=20.1 Hz), 133.97, 133.74, 130.08 (d, J=4.5 Hz), 129.62 
(d, J=4.1 Hz), 128.96, 128.84 (d, J=3.6 Hz), 128.75, 128.59, 128.40, 128.35, 128.29, 
127.60, 125.99, 124.23, 57.79, 52.32, 31.61, 19.07, 18.17. 31PNMR (202 MHz, CDCl3) δ 





Scheme 5.23 Synthesis of meta-substituted aniline Ru complex (23) 
 
 
Phosphine ligand (12.7 mg, 0.020 mmol), Ru starting material (15.0 mg, 0.020 mmol), and 
CHCl3 (3 mL) were added to a small glass vial and stirred under dark conditions for 30 
min. Following this, components were separated by silica gel chromatography (3:1 
CHCl3:EtOAc). The resulting red intermediate complex was then added to a small glass 
vial and stirred under a desk lamp (650 lumin) for 4h. This mixture was then separated by 
silica gel chromatography (1:1 CHCl3:EtOAc) to yield a yellow product (7.2 mg, 44 % 
yield). 1HNMR (500 MHz, CDCl3) δ 8.61 (s, 1H), 8.51 (d, J = 1.4 Hz, 2H), 7.76 (dd, J = 
7.6, 1.8 Hz, 1H), 7.72 (d, J = 7.8 Hz, 4H), 7.69 – 7.63 (m, 3H), 7.63 – 7.56 (m, 2H), 7.51 
– 7.45 (m, 1H), 7.45 – 7.40 (m, 2H), 7.37 – 7.30 (m, 7H), 7.28 – 7.22 (m, 2H), 7.15 (t, J = 
7.4 Hz, 2H), 6.80 (d, J = 6.2 Hz, 1H), 6.27 (t, J = 5.8 Hz, 1H), 5.56 (s, 1H), 5.50 (d, J = 5.6 
Hz, 1H). 13CNMR (126 MHz, CDCl3) δ 164.89, 144.61, 144.21, 143.86, 143.68, 138.16, 
138.07, 135.93, 134.30, 134.28, 134.03, 133.95, 133.64, 133.56, 133.05, 131.66, 131.40, 
131.19, 131.17, 130.93, 130.91, 130.41, 130.36, 130.30, 130.01, 129.30, 128.91, 128.47, 
128.38, 128.32, 128.17, 128.08, 127.77, 127.67, 124.76, 121.10, 121.00, 120.98, 112.31, 
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110.40, 110.38, 95.40, 90.75, 90.63, 80.75, 78.98. 31PNMR (202 MHz, CDCl3) δ 53.19. 




Scheme 5.24 Synthesis of meta-substituted benzylamine Ru complex (24) 
 
Phosphine ligand (16.7 mg, 0.024 mmol), Ru starting material (15.8 mg, 0.024 mmol), and 
CHCl3 (3 mL) were added to a small glass vial and stirred under dark conditions for 30 
min. Following this, components were separated by silica gel chromatography (1:1 
CHCl3:EtOAc). The resulting red intermediate complex was then added to a small glass 
vial and stirred under a desk lamp (650 lumin) for 4h. This mixture was then separated by 
silica gel chromatography (1:1:0.05 CHCl3:EtOAc:MeOH) to yield a yellow product (12.8 
mg, 60 % yield). 1HNMR (500 MHz, CDCl3) δ 8.44 (s, 1H), 8.41 (s, 2H), 7.76 (d, J = 7.3 
Hz, 1H), 7.71 – 7.63 (m, 3H), 7.60 – 7.55 (m, 2H), 7.47 (d, J = 6.8 Hz, 1H), 7.45 – 7.40 
(m, 2H), 7.37 – 7.28 (m, 12 H), 7.28 – 7.22 (m, 5H), 6.68 (d, J = 5.8 Hz, 1H), 6.19 – 6.14 
(m, 1H), 5.54 – 5.48 (m, 2H), 4.68 – 4.61 (m, 2H), 4.59 (m, 2H). 13CNMR (126 MHz, 
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CDCl3) δ 166.35, 144.60, 144.20, 143.76 (d, J=22.2Hz), 138.26, 135.19, 134.17, 134.01 
(d, J=9.9 Hz), 133.58 (d, J=9.8 Hz), 133.03, 131.63, 131.19, 130.83, 130.35, 130.30, 
128.99, 128.62, 128.45 (d, J=10.9 Hz), 128.10, 128.01, 127.81, 127.74, 127.63, 127.35, 
113.69, 110.52 (d, J=2.8 Hz), 94.58, 90.46, 90.35, 80.86, 78.57, 44.08. 31PNMR (202 
MHz, CDCl3) δ 53.32. HRMS (ESI): Found m/z 817.1320. Calcd. for C46H37ClN2O2PRu 
: (M-Cl) 817.1319 
 
 
Scheme 5.25 Synthesis of meta-substituted phenylethylamine Ru complex (25) 
 
Phosphine ligand (24 mg, 0.034 mmol), Ru starting material (21.9 mg, 0.034 mmol), and 
CHCl3 (2 mL) were added to a small glass vial and stirred under dark conditions for 30 
min. Following this, components were separated by silica gel chromatography (1:1 
CHCl3:EtOAc). The resulting red intermediate complex was then added to a small glass 
vial and stirred under a desk lamp (650 lumin) for 4h. This mixture was then separated by 
silica gel chromatography (1:1 CHCl3:EtOAc) to yield a yellow mixture of diastereomers 
(10.6 mg and 11.8 mg, total=22.4 mg, 74 % yield). Diastereomer 1 (lower spot on TLC) 
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1HNMR (500 MHz, CDCl3) δ 8.45 (s, 2H), 8.28 (s, 1H), 7.73 – 7.68 (m, 1H), 7.68 – 7.60 
(m, 3H), 7.60 – 7.55 (m, 2H), 7.49 – 7.43 (m, 1H), 7.43 – 7.38 (m, 2H), 7.34 (d, J = 7.5 
Hz, 4H), 7.32 – 7.25 (m, 9H), 7.24 – 7.15 (m, 6H), 6.66 (d, J = 6.1 Hz, 1H), 6.20 (t, J = 5.8 
Hz, 1H), 5.47 (d, J = 5.6 Hz, 1H), 5.44 (s, 1H), 5.31 – 5.23 (m, 2H), 1.57 (d, J = 7.0 Hz, 
6H). 13CNMR (126 MHz, CDCl3) δ 165.09, 145.06, 144.65, 143.79 (d, J=21.6 Hz), 143.12, 
135.30, 134.58, 134.57, 134.01, 133.93, 133.72 (d, J=10.2 Hz), 132.97, 131.48, 131.14, 
131.03, 130.76 (d, J=2.9 Hz), 130.15 (d, J=6.8 Hz), 128.65, 128.29 (d, J=10.9 Hz), 128.04, 
127.96, 127.65, 127.56, 127.28, 126.94, 126.25, 109.62, 91.28, 81.26, 49.87, 22.12. 
31PNMR (202 MHz, CDCl3) δ 52.72. HRMS (ESI): Found m/z 845.1622. Calcd. for 
C48H41ClN2O2PRu: (M-Cl) 845.1632. Diastereomer 2 (higher spot on TLC) 1HNMR (500 
MHz, CDCl3) δ 8.33 (s, 3H), 7.69 (d, J = 6.2 Hz, 1H), 7.60 (dd, J = 11.8, 7.2 Hz, 4H), 7.57 
– 7.52 (m, 2H), 7.49 – 7.38 (m, 6H), 7.35 (d, J = 7.5 Hz, 5H), 7.34 – 7.28 (m, 7H), 7.22 (t, 
J = 7.3 Hz, 2H), 6.99 (d, J = 4.8 Hz, 1H), 6.69 (s, 1H), 5.52 (s, 1H), 5.36 (d, J = 5.6 Hz, 
1H), 5.26 (p, J = 6.9 Hz, 2H), 1.54 (d, J = 7.0 Hz, 6H). 13CNMR (126 MHz, CDCl3) δ 
164.96, 144.63, 144.24, 143.81 (d, J=22.0 Hz), 143.42, 134.97, 134.24, 133.87 (d, J=,9.6 
Hz) 133.71, 133.63, 133.02, 131.44, 131.12, 130.92-130.87 (m), 130.74 (d, J=2.9 Hz), 
130.18, 130.13, 129.95, 129.64, 129.54, 129.25, 128.62, 128.28, 128.22 (dd, J=10.9, 5.4 
Hz), 128.15, 127.66, 127.53, 127.43, 127.21, 126.26, 111.83, 111.82, 110.61, 97.74, 89.87, 
79.07, 50.02, 22.05. 31PNMR (202 MHz, CDCl3) δ 53.47. HRMS (ESI): Found m/z 






Scheme 5.26 Synthesis of glycine Ru complex (26) 
 
Phosphine ligand (50 mg, 0.074 mmol), Ru starting material (95.7 mg, 0.148 mmol), and 
CHCl3 (5 mL) were added to a small glass vial and stirred under dark conditions for 30 
min. Following this, components were separated by silica gel chromatography (1:1 
CHCl3:EtOAc). The resulting red intermediate complex was then added to a small glass 
vial and stirred under a desk lamp (650 lumin) overnight. This mixture was then separated 
by silica gel chromatography (1:1 CHCl3:EtOAc) to yield a yellow product (34.3 mg, 55 
% yield). 1HNMR (500 MHz, CDCl3) δ 8.44 (s, 1H), 8.41 (s, 2H), 7.74 (s, 1H), 7.69 (dd, 
J = 11.0, 7.7 Hz, 2H), 7.66 – 7.62 (m, 1H), 7.62 – 7.55 (m, 2H), 7.46 (d, J = 6.2 Hz, 1H), 
7.43 (d, J = 6.2 Hz, 2H), 7.35 (s, 1H), 7.32 – 7.23 (m, 6H), 6.69 (d, J = 5.1 Hz, 1H), 6.17 
(t, J = 5.3 Hz, 1H), 5.52 (d, J = 5.3 Hz, 1H), 5.47 (s, 1H), 4.26 – 4.06 (m, 8H), 1.29 (t, J = 
7.1 Hz, 6H). 13CNMR (126 MHz, CDCl3) δ 169.78, 166.49, 144.66, 143.78 (d, J=21.8 Hz), 
134.63, 134.24, 134.07, 133.99, 133.57 (d, J=9.6 Hz), 132.98, 131.54, 131.15, 130.88, 
130.79, 130.48, 130.24 (d, J=6.8 Hz), 128.43 (d, J=10.8 Hz), 128.07, 127.98, 127.73, 
127.64, 113.41, 110.26, 94.58, 90.60 (d, J=14.5 Hz), 80.97, 78.82, 61.46, 41.96, 14.18. 
 
94 
31PNMR (202 MHz, CDCl3) δ 53.35. HRMS (ESI): Found m/z 809.1116. Calcd. for 
C40H37N2Cl1O6PRu :(M-Cl) 809.1116 
 
 
Scheme 5.27 Synthesis of meta-substituted valine Ru complex (27) 
 
Phosphine ligand (50 mg, 0.069 mmol), Ru starting material (44 mg, 0.069 mmol), and 
CHCl3 (5 mL) were added to a small glass vial and stirred under dark conditions for 30 
min. Following this, components were separated by silica gel chromatography (1:1 
CHCl3:EtOAc). The resulting red intermediate complex was then added to a small glass 
vial and stirred under a desk lamp (650 lumin) overnight. This mixture was then separated 
by silica gel chromatography (1:1 CHCl3:EtOAc) to yield a yellow product (48.1 mg, 74 
% yield). 1HNMR (500 MHz, CDCl3) δ 8.49 (s, 2H), 8.35 (d, J = 19.9 Hz, 1H), 7.71 (d, J 
= 6.9 Hz, 1H), 7.67 – 7.55 (m, 4H), 7.46 – 7.28 (m, 5H), 7.25 – 7.16 (m, 2H), 7.09 (d, J = 
8.2 Hz, 1H), 7.02 (d, J = 8.2 Hz, 1H), 6.68 (dd, J = 15.5, 5.6 Hz, 1H), 6.23 (dt, J = 19.3, 
5.6 Hz, 1H), 5.50 – 5.45 (m, 2H), 4.70 – 4.65 (m, 2H), 3.75 (d, J = 7.7 Hz, 6H), 2.30 – 2.21 
(m, 2H), 1.01 – 0.96 (m, 12H). 13CNMR (126 MHz, CDCl3) δ 172.00, 166.14, 165.95, 
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145.19, 144.79, 143.89 (d, J=21.6 Hz), 134.94, 134.82, 134.80, 134.04, 133.99 (dd, J=9.9, 
2.4 Hz), 133.95, 133.88, 133.80, 132.99, 132.94, 131.54, 131.45 (d, J=4.8 Hz), 130.99, 
130.96, 130.94, 130.70, 130.46, 130.16, 130.12, 130.07, 129.76, 129.67, 129.36, 128.30, 
128.24 (dd, J=10.9, 4.5 Hz), 128.18, 128.04, 127.99 (dd, J=11.0, 2.4 Hz), 127.94, 127.71, 
127.64 (dd, J=12.6, 4.6 Hz), 127.07, 126.94, 111.08 (d, J=4.4 Hz), 110.19, 109.39 (t, J=2.7 
Hz), 96.05, 95.39, 91.62, 91.54 (dd, J=14.3, 6.2 Hz), 81.57 (d, J=10.8 Hz), 79.96 (d, J=28.8 
Hz), 58.33, 58.28, 52.29, 52.21, 31.16, 31.12, 19.15, 19.14, 18.33, 18.26. 31PNMR (202 
MHz, CDCl3) δ 52.63, 52.23. HRMS (ESI): Found m/z 865.1747. Calcd. for 
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A.1 1HNMR spectra 
 













Figure A.2 Amine 4 
 




Figure A.4 Silane 7a 
 




Figure A.6 Silane 7c 
 




Figure A.8 Silane 7e 
 




Figure A.10 Silane 7g 
 




Figure A.12 Silane 7i 
 




Figure A.14 Silane 7k 
 




Figure A.16 Silane 7m 
 




Figure A.18 Silane 7o 
 




Figure A.20 Amine 8a 
 




Figure A.22 Amine 8c 
 




Figure A.24 Amine 8e 
 




Figure A.26 Amine 8g 
 




Figure A.28 Amine 8i 
 




Figure A.30 Amine 8k 
 




Figure A.32 Amine 8m 
 




Figure A.34 Amine 8o 
 
Figure A.35 Amine 8p 
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A.2 13CNMR spectra 
 














Figure A.37 Amine 4 
 




Figure A.39 Amine 8b 
 




Figure A.41 Silane 7d 
 




Figure A.43 Silane 7f 
 




Figure A.45 Silane 7h 
 




Figure A.47 Silane 7j 
 




Figure A.49 Silane 7l 
 




Figure A.51 Silane 7n 
 




Figure A.53 Silane 7p 
 




Figure A.55 Amine 8b 
 




Figure A.57 Amine 8d 
 




Figure A.59 Amine 8f 
 




Figure A.61 Amine 8h 
 




Figure A.63 Amine 8j 
 




Figure A.65 Amine 8l 
 




Figure A.67 Amine 8n 
 






















B.1 1HNMR spectra 
 




Figure B.2 Intermediate 2 
 




Figure B.4 Intermediate 4 
 




Figure B.6 Ligand 6 
 




Figure B.8 Ligand 8 
 




Figure B.10 Ruthenium complex 12 
 




Figure B.12 Ruthenium complex 10 
 




Figure B.14 Ruthenium complex 14 
 




Figure B.16 Intermediate 16 
 




Figure B.18 Ligand 20 
 




Figure B.20 Ligand 18 
 




Figure B.22  Ligand 22 
 




Figure B.24 Ruthenium complex 25/Diastereomer 2 
 




Figure B.26 Ruthenium complex 23 
 








B.2 13CNMR spectra 
 




Figure B.30 Intermediate 3 
 




Figure B.32 Ligand 7 
 




Figure B.34 Ligand 5 
 




Figure B.36 Ligand 9 
 




Figure B.38 Ruthenium complex 11 
 




Figure B.40 Ruthenium complex 13 
 




Figure B.42 Intermediate 15 
 




Figure B.44 Intermediate 17 
 




Figure B.46 Ligand 19 
 




Figure B.48 Ligand 21 
 




Figure B.50 Ruthenium complex 25/Diastereomer 1 
 




Figure B.52 Ruthenium complex 24 
 




Figure B.54 Ruthenium complex 26 
 
Figure B.55 Ruthenium complex 27 
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B.3 31PNMR spectra 
 
 




Figure B.57 Ligand 7 
 




Figure B.59 Ligand 8 
 




Figure B.61 Ruthenium complex 12 
 




Figure B.63 Ruthenium complex 10 
 




Figure B.65 Ruthenium complex 14 
 




Figure B.67 Ligand 20 
 




Figure B.69 Ligand 18 
 




Figure B.71 Ligand 22 
 




Figure B.73 Ruthenium complex 25/Diastereomer 2 
 




Figure B.75 Ruthenium complex 23 
 




Figure B.77 Ruthenium complex 27 
